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Abstract 
Keywords: Matrix Metalloproteinase, Histone Deacetylase, NSCLC 
Matrix Metalloproteinase-10 (MMP-10) has been shown to be overexpressed in hu-
man non-small cell lung cancer (NSCLC), wherein it is proteolytically active, secreted 
predominantly by tumour cells, and implicated in retarding angiogenesis through re-
pression of tumour vasculature development. Previous studies have indicated a role 
for the histone deacetylase (HDAC) enzymes, specifically HDAC7, in the regulation of 
MMP-10, with elevated levels of HDAC7 repressing MMP-10 expression and promot-
ing successful blood vessel formation. The aim of this project was to evaluate the 
relationship between MMP-10 and HDACs and whether perturbation of the 
HDAC7/MMP-10 pathway maybe a viable opportunity for therapeutic exploitation in 
NSCLC. Using an in vitro model of NSCLC a central role for histone deacetylases 
(HDACs) in regulation of MMP-10 expression was confirmed. Although inhibition of 
HDAC activity increased MMP-10 expression and activity, selective inhibition of the 
class-II HDAC7 had no effect. However, siRNA-mediated repression of HDAC7 expres-
sion caused a significant elevation in MMP-10 expression and activity, supporting a 
central role for the presence but not enzymatic activity of HDAC7 in the control of 
MMP-10 levels within NSCLC. Despite the lack of a role for HDAC7 enzyme activity in 
control of MMP-10, the initial observation that pan-inhibition of HDAC activity re-
pressed MMP-10 expression implicated a wider involvement for HDACs in regulation 
of MMP-10. Consequently, this study using both siRNA and pharmacological inhibi-
tors confirmed an additional role for the presence and enzymatic activity of the class-
I subfamily member HDAC3 in the regulation of MMP-10 in NSCLC. These data indi-
cated an interplay between the class-I HDAC3 and class-II HDAC7 in the regulation of 
MMP-10 expression and activity, a relationship supported by the previously sug-
gested role for HDAC7 in the nuclear shuttling and subsequent enzymatic functional-
ity of HDAC3. This study thereby identifies and offers a novel molecular mechanism 
for HDAC-mediated control of MMP-10 in NSCLC. Further work is required to exploit 
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Chapter I - Introduction  
I.1 Cancer 
Cancer is a very complex disease that can occur anywhere in the body, with a very 
diverse range of causes including tobacco smoke, genetic abnormalities, and infec-
tions such as the papillomavirus, amongst others (Anand et al., 2008; zur Hausen, 
1996). It is defined as the ‘uncontrolled and invasive growth of cells’ with the ability 
to metastasise to other areas of the body, causing secondary growths (Patyar et al., 
2010; Coussens & Werb, 2002). 
 There are reportedly over 200 different pathological types of human cancer 
affecting all tissues of the body, with approximately 350,000 new cases of adult and 
paediatric cancers diagnosed per year in the UK (Cancer Research UK, 2014). Further-
more, cancer is the second major cause of mortalities, responsible for the deaths of 
approximately 162,000 people in the UK per year. Consequently, it is now estimated 
that one person in three will be diagnosed with cancer during their lifetime and one 
in four will die of cancer. As a consequence of extended life expectancy and an in-
crease in the global population, it is also predicted that over the next decade the 
prevalence of cancer would significantly increase, but due to better prediction and 
treatment the number of deaths from cancer should hopefully decrease (Lin et al., 
2009; Ferlay et al., 2013).  
 
I.1.1 Non-Small Cell Lung Carcinoma 
Non-small cell lung carcinoma (NSCLC) accounts for approximately 80% of lung can-
cers and is the number one cause of cancer related mortalities (Herbst et al., 2008; 
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Bray et al., 2013; Perez-Soler, 2009). NSCLC is subdivided into several sub-types 
based on their histological appearance; adenocarcinomas, squamous cell, bronchio-
alveolar and large cell carcinomas (Travis, 2002). Adenocarcinomas derive from glan-
dular epithelia (Weinberg, 2014) and are the most frequent NSCLC sub-type re-
ported, accounting for 40% of clinical lung cancer cases (Lu et al., 2010). Squamous 
cell carcinomas make up 25-30% of clinical lung cancer cases and develop primarily 
in epithelial cells that line and protect the underlying cell populations, such as the 
bronchial tree. Large cell carcinomas, otherwise known as undifferentiated carcino-
mas, account for 10-15% of cases.  
 Several features of NSCLC, in particular primary tumour size; tumour grade; 
regional lymph node involvement; presence of metastasis and tumour pathology are 
known to influence response to therapy and patient survival. Although treatment in 
the majority of NSCLC cases involves a chemotherapeutic regimen, response in many 
cases is often poor, with adenocarcinomas tending to have a better prognosis than 
large cell carcinoma or squamous cell carcinoma (Cetin et al., 2011). As a conse-
quence, better understanding of the molecular pathology of NSCLC, determination 
of novel tumour markers and identification of targets for therapeutic exploitation are 
central to improving diagnosis and treatment of this cancer type. Over the past dec-
ade, a large number of newer molecular targeted treatments addressing molecular 
determination of NSCLC have been developed to supplement ‘conventional’ DNA-
damaging cytotoxic drugs in the treatment of NSCLC (Hanahan & Weinberg, 2011). 
For instance, Bevacizumab (Avastin®) is now licensed for the treatment of NSCLC and 
targets the depending of tumour growth upon new blood vessel formation (Di Cos-
tanzo et al., 2008). Bevacizumab was found to increase the survival rate of patients 
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approximately 2-4 months, dependent upon the type of NSCLC it was used to target 
(Sandler et al., 2006). More recently, molecular-targeted therapeutics against NSCLC 
have shown symptom improvement in advanced NSCLC patients.  One molecular tar-
get is the epidermal growth factor receptor (EGFR), a cell membrane receptor tyro-
sine kinase, which has been found to be up-regulated in certain cases of NSCLC, sug-
gesting that the EGFR-mediated pathway might play an important role in lung carcin-
ogenesis. High expression levels of EGFR, led to the development of tyrosine kinase 
inhibitors; Erlotinib (Tarceva®) and Gefitinib (Iressa®), these inhibit the tyrosine ki-
nase activity of EGFR and have shown significantly prolonged progression-free sur-
vival and achieved higher responses than chemotherapy (Baumgart, 2015; Cascone 
et al., 2006; Gridelli et al., 2007; Maemondo et al., 2010; Zhou et al., 2011). However, 
greater knowledge of NSCLC pathophysiology is still required to better understand 
this disease and develop more efficacious treatment.  
 
I.2 Molecular basis of cancer  
Despite the wide range of ‘causes’ and ‘types’ of cancer, and diversity amongst indi-
viduals, cancer fundamentally derives from molecular aberrations within susceptible 
cells. In principle, non-lethal genetic damage causes modifications to key pathways 
inside the cell, which, in turn, result in lack of normal regulation of cell growth, con-
ferring a survival advantage to the affected cells, and progressively the ability to in-
vade neighbouring tissues and disseminate to other parts of the body. 
 Several types of alteration can affect the genome within these tumour cells, 
leading to cellular transformation and subsequently a selected growth advantage. 
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The types of genes affected are roughly categorised into two groups, those which 
promote uncontrolled cell growth (oncogenes) and those which inhibit tumour 
growth (tumour suppressor genes). The contrasting balance in the activity and re-
pression of these two opposing gene categories drives the molecular evolution of 
cancer. However, although cancer is without doubt a genetic disease, genetic regu-
lation involves a multitude of control factors, including epigenetic mechanisms (i.e. 
heritable changes in gene expression determined by factors other than alteration of 
the primary DNA sequence). In the same manner that DNA mutations are important, 
epigenetic changes can similarly control gene expression and thus cancer develop-
ment (Sharma et al., 2010). Epigenetic regulation is largely controlled by two pro-
cesses, alteration in chromatin structure to regulate the access of the transcriptional 
machinery to the DNA (post-translational modification of histones), and direct epi-
genetic modification of DNA through methylation of specific nucleotides (DNA meth-
ylation). Hypermethylation of CpG islands is common in the promoter region of many 
genes, preventing the recruitment of transcription factors, which is commonly in-
volved with loss of tumour suppressor function. The post-translational modification 
of histones, the charged proteins around which negatively-charged DNA is packaged, 
effects nucleosome aggregation and compaction, dictating transcriptional activity of 
specific genes (Mottis et al., 2013). Cancer is linked to histone hypoacetylation and 
repression of several key tumour suppressor genes (Ropero & Estellar, 2007). To-
gether the concerted interactions of genetic and epigenetic changes are driving 
forces for cancer development.  
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I.2.1 The hallmarks of cancer 
Cancerous cells during replication do not adhere to the regulated processes involved 
with normal formation of eukaryotic cells, with evasion of critical checkpoints allow-
ing the cells to carry on replicating their mutated DNA uncontrollably and gaining the 
capability to invade neighbouring tissues and metastasise to distant organs (Wein-
berg, 2014; Park & Lee, 2003). Hanahan and Weinberg originally identified six defin-
itive hallmarks of cancer as distinctive biological capabilities of a tumour cell, defined 
as: limitless replicative potential; self-sufficiency in growth signals; insensitivity to 
anti-growth signals; evasion of cell death; development of sustained angiogenesis 
and, the ability to invade and metastasise (Hanahan & Weinberg, 2000). A decade 
later two further hallmarks were added, de-regulation of cellular energetics, and the 
ability to avoid destruction by the immune system (Hanahan & Weinberg, 2011). Ad-
ditionally, two enabling characteristics were also identified, genome instability which 
generates the genetic diversity that expedites their acquisition, and tumour-promot-
ing inflammation, which fosters multiple hallmark functions (Hanahan & Weinberg, 
2011). In addition to cancer cells, tumours also exhibit another dimension of com-
plexity: they contain a repertoire of recruited, ostensibly normal cells that contribute 
to the acquisition of hallmark traits by creating the "tumour microenviron-
ment”’(Hanahan & Weinberg, 2011).  
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Figure I.1. Hallmarks of cancer and enabling characteristics [adapted from Hanahan 
and Weinberg, 2011] 
 
 
I.2.1.1 Tumour cell proliferation and survival 
Despite the complex nature of cancer, it is often simplistically characterised as the 
uncontrolled growth of cells with the consequent development of a tumour. How-
ever, uncontrolled cell growth is far from simple and results from the deregulation 
of a number of closely controlled features. These include the prevention of replica-
tion limiting features, the development of cellular insensitivity to anti-growth signals 
and the evasion of programmed cell death (Sonnenschein & Soto, 2013). 
 Cancer cells employ several strategies to drive proliferation and overcome 
insensitivities to normal growth regulation, with the ultimate aim being to move all 
cells into, and then through the cell cycle, culminating in production of new daughter 
cells.  During cancer development, dysregulation of the cell cycle checkpoints, 
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through mutations or genetic aberrations, accelerate the accumulation of further 
mutations, leading to oncogene activation and tumour suppressor gene inactivation. 
For instance, the tumour suppressor, p53, is a key regulator of both the G1-S and G2-
M checkpoints; p53 is, however, inactivated in over half of clinical cancers, allowing 
cells with damaged and mutated DNA to replicate and produce daughter cells (Rivlin 
et al., 2011). 
 Cellular proliferation is managed through the receipt of growth factors and 
subsequent stimulation of signalling pathways, with the tyrosine kinase class being 
the predominant players in this area (e.g. epidermal growth factor, EGF; Vascular en-
dothelial growth factor, VEGF etc.). Under normal circumstances, the binding of 
these factors to the specific receptor on the cell surface (e.g. epidermal growth factor 
receptor, EGFR) provides transient receptor activation, with the signal thereafter be-
ing transduced from the cell membrane to the nucleus initiating activation of the cell 
cycle and cellular division (Lemmon & Schlessinger, 2010). Under normal circum-
stances, the vast majority of proliferation-inducing growth factors act in a paracrine 
fashion to stimulate proliferation of another cell type. However, a major mechanism 
by which cancer cells acquire self-sufficiency is through gaining the ability to both 
synthesize and respond to a particular growth factor, creating an autocrine loop 
(Brooksbank, 2001). In a second tumorigenic mechanism, some cancer cells interact 
with their microenvironment and ‘falsely’ stimulate normal cells to produce growth 
factors and subsequently promote cancer development. Further mechanisms associ-
ated with this cancer hallmark (self-sufficiency in growth signals) include the gain of 
an activating mutation (creating an oncogenic protein) in the receptor or alterna-
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tively through increased expression of the receptor (gene duplication or chromoso-
mal translocation). In these situations, cells either ‘override’ the normal proliferative 
control mechanisms (and gain independence from the external growth factor), or are 
rendered hyper-responsive to levels of the growth factor that would not normally 
trigger proliferation. A further common mechanism associated with autonomy to 
growth signals is through genetic alterations or epigenetic modifications of genes 
linking growth factor receptors to the effector mechanisms of mitogenesis in the nu-
cleus. Such changes activate the downstream signalling pathway, effectively mimick-
ing the growth promoting effects of growth factor pathway activation.  
 In the same way cells receive signals to promote proliferation and progress 
through the cell cycle, they also must receive messages to inhibit, retard or leave the 
cell cycle. Effectively these signals are provided by tumour suppressor genes, with 
their disruption making the cells refractory to their growth inhibitory activity and 
theoretically making them mimic the effects of oncogene activation (Levine et al., 
1991). Inappropriate proliferation of cells or persistence of those with genetic muta-
tions is normally controlled by the tightly regulated process of programmed cell 
death or apoptosis (Duronio & Xiong, 2013). These pathways are initiated as a re-
sponse to extracellular stresses such as limitation of growth factors, oxygen or nutri-
ents, or intracellular stresses such as DNA damage or telomere shortening (Borges et 
al., 2008). In cancer cells, defects in these pathways confer resistance to apoptosis, 
thereby allowing unchecked cellular replication of cells either with damaging muta-
tions or tumorigenic phenotype (Fulda, 2009). 
 Another trait of cancer cells is the capacity for limitless replication and prolif-
erative capacity (Hanahan & Weinberg, 2001). In ‘non-tumorigenic’ cells, the number 
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of cellular divisions each cell can undergo is normally restricted, regulated by specific 
DNA sequences at the termini of chromosomes called telomeres (O’Sullivan & 
Karlseder, 2010). Shortening of these telmomeric sequences causes cell cycle arrest, 
and senescence (O’Sullivan & Karlseder, 2010). Cancer cells demonstrate capability 
to renew telomeres in order to ensure their continued reproductive capacity, 
through upregulation of the enzyme telomerase (Jafri et al., 2016).  
  
I.2.1.2 Angiogenesis 
In order for cells to survive they must be within close proximity of a blood (or lym-
phatic) vessel, to allow maximal diffusional delivery of nutrients and oxygen or clear-
ance of waste products (Kerbel, 2000). In agreement with normal cells, this concept 
is also applicable to cancer, as tumours cannot grow to a diameter larger than 1-2mm 
unless they have a vascular supply (Kerbel, 2000). The issue that exists with cancer is 
that the ever increasing tumours mass subsequently needs a larger and larger blood 
supply to support this rapidly expanding tumour mass (Nishida et al., 2006). 
 Angiogenesis is the formation of new blood vessels from existing vessels in-
volved in blood vessel formation in development and disease and is one of the fun-
damental hallmarks of cancer (Carmeliet & Jain, 2000). In contrast to pathogenic an-
giogenesis, the development of blood vessels during embryo development involves 
recruitment of endothelial cells from immature precursor cells located within the 
bone marrow, a process termed vasculogenesis (Jain, 2003). Although vasculogenesis 
has been suggested to show an involvement in tumorigenesis, it is angiogenesis 
which predominates. Angiogenesis, which under normal circumstances is a highly 
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regulated process, is continuously triggered in the rapidly growing tumour. The en-
suing hypoxia developing in the tumour, as it reaches the ‘critical’ size limited by dif-
fusional restraints, prevents destruction of the oxygen-sensitive transcription factor, 
hypoxia-inducible-factor 1 (HIF-1α), which subsequently relocates to the nucleus and 
initiates expression of vascular endothelial growth factor (VEGF) (Krock et al., 2011). 
Therefore, until the tumour mass reaches this critical size associated with ‘supply and 
demand’ there is no requirement for further blood vessels. Once the tumour hits this 
critical size the ‘Angiogenic Switch’ is triggered, allowing the balance of pro-angio-
genic factors to exceed anti-angiogenic factors (Baeriswyl & Christofori, 2009). The 
elevated production and secretion of VEGF from tumour cells and the surrounding 
microenvironment activates VEGF-receptors (VEGFR) on the endothelial cell surface, 
subsequently leading to increased permeability and vasodilation, loosening of endo-
thelial cell contacts, and finally sprouting of endothelial cells from the existing vessels 
(Bates, 2010). Simultaneously, increased levels of VEGF (and other pro-angiogenic 
factors, such as basic fibroblast growth factor, bFGF) stimulate the release of prote-
olytic enzymes, including the serine protease plasmin and several zinc-dependent 
matrix metalloproteinases (MMPs) (Vempati et al., 2010) (figure I.2). The ‘cleared 
pathway’ created by these proteases permits the migration of the proliferative en-
dothelial cells in the direction of the tumour mass, up a gradient of chemokinetic 
factors released from the tumour, forming ‘migration columns’ and primitive blood 
vessels (Ucuzian et al., 2010). Completion of the ‘column’ between the established 
vessel and the tumour mass leads to endothelial cell differentiation, involving mor-
phological alterations and resultant adherence of these cells to form the lumen of 
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the vessel. Finally, the newly developed vessels are stabilised via recruitment of per-
icytes (smooth muscle related cells) to the external surface of endothelium. How-
ever, in tumour angiogenesis there is a decreased association of pericytes with the 
newly formed and immature vessels (compared to mature ‘normal’ blood vessels) 
(Bergers & Song, 2005). 
 Unlike ‘normal’ processes, the resulting vasculature initiated in the tumour, 
due to rapidity of tumour growth, is, however, abnormal, poorly organised, chaotic, 
and leaky (Nagy et al., 2009). Furthermore, in addition to facilitating and supporting 
tumour growth and expansion, the newly developed neovasculature increases the 
‘escape routes’ for tumour cells and, by default, facilitates tumour malignancy and 
the spread of tumour cells to other parts of the body (metastasis) (Nishida et al., 
2006). 
 Angiogenesis is a viable therapeutic target for cancer treatment because of 
the fact tumour progression is dependent upon its presence (Cross & Claesson-
Welsh, 2001); therefore, if this stage could be halted the cancer would not be able 
to survive due to the lack of essential nutrients.  
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Figure I.2 Tumour Angiogenesis. Tumour cells release pro-angiogenic factors (e.g. 
VEGF) which bind to receptors on the endothelial cells of pre-existing blood vessels 
(VEGFR). This leads to secretion and activation of proteolytic enzymes, e.g. matrix 
metalloproteinases; MMPs, which degrade the extracellular matrix (ECM), allowing 
migration of endothelial cells. The existing vasculature is supported by pericytes, 
whereas the developing angiogenic blood vessel secretes growth factors, e.g. plate-
let-derived growth factor; PDGF, which attracts these supporting cells and pericytes 
to stabilize the new vessel. 
 
I.2.1.3 Metastasis: Carcinoma in situ becomes an invasive carcinoma 
Uncontrolled cell growth is not necessarily hazardous to the wellbeing of the patient 
(Chambers et al., 2002). Indeed, benign tumours grow without the ability to invade 
neighbouring tissues or relocate from their resident location to another site within 
the body. However, by definition, malignant cancer cells exhibit the ability to spread, 
show invasive potential and, ultimately, metastasise to distant regions of the body 
(Martin et al., 2013). Metastasis is the major cause of cancer mortality and, if present, 
dramatically worsens the prognosis for the patient; compared to if the cancer was 
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diagnosed prior to metastatic spread. However, it is often the case that metastasis is 
present by the time the primary cancer has been diagnosed (Friberg & Nystrom, 
2015). It is these secondary metastases not the primary tumours that are the main 
attribute towards mortality and they are found to be responsible for 90% of cancer 
associated deaths (Yilmaz et al., 2007). 
 The process of metastasis is a series of rate-limiting steps that must occur in 
order for cancer to disseminate to sites, other than the primary tumour. Tumour me-
tastasis follows a set pattern of processes: i) The primary tumour forms an avascular 
mass acquiring its nutrients from the host tissue. Tumour expansion increases hy-
poxia within this mass, a major driver of several elements of the metastatic process 
(Eales et al., 2016), leading to activation of the angiogenic switch (Baeriswyl & Chris-
tofori, 2009). The resultant vascularisation of the tumour increases its scope for ex-
pansion and, ultimately, malignancy. ii) Next, as the tumour grows it acquires further 
genetic aberrations which provide it with the potential and tools to gain mobility and 
often trigger a conversion and transition from an epithelial to mesenchymal (EMT) 
phenotype. The EMT is a complex pathway during which epithelial cells lose their 
differentiated characteristics and acquire mesenchymal features, which include mo-
tility, invasiveness, and resistance to apoptosis (Martin et al., 2013). Currently, it ap-
pears that EMT-inducing transcription factors can coordinate the majority of steps in 
the invasion/metastatic cascade (Martin et al., 2013). iii) The acquisition of mobility 
and ability to invade through tissues, eventually results in the tumour cell(s) breach-
ing the local basement membrane and transiting towards blood and lymphatic ves-
sels. iv) Tumour cells can then intravasate from the ‘invaded tissue’ into the circula-
tion (or lymphatic system), wherein they adhere to endothelial cells and platelets 
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and eventually transit through the vasculature until becoming ‘trapped’ or ‘depos-
ited’ in capillaries of another tissue, whereby they extravasate out of the blood vessel 
and into the new host tissue (Gupta & Massague, 2006). 
 From a molecular perspective, tumour malignancy is effectively two capabili-
ties grouped together, the initial ability of tumour cells to move and invade into 
neighbouring tissue (local invasion) and then secondly, the ability to move from one 
site and disseminate to another (metastasis). Both invasion and metastasis are de-
pendent upon many molecular factors to allow movement and negotiation through 
the surrounding supportive extracellular matrix (ECM) (Egeblad & Werb, 2002). This 
supportive network comprises of two main classes of extracellular macromolecules, 
the first are the polysaccharide chains of the class called glycosaminoglycans (GAGs), 
which are usually found covalently linked to protein in the form of proteoglycans and 
secondly the fibrous proteins, including collagen and elastin which both have struc-
tural and adhesive functions (Alberts et al., 2002).  Additional elements can be pre-
sent in the ECM depending upon the cell origin, for example the ECM of the bones 
also contains mineral deposits (Frantz et al., 2010).  
 Following successful transit of the cells through the ECM, metastasis pro-
gresses by vascular dissemination of these cells to other sites (Valastyan & Weinberg, 
2011). Although the most common route for metastatic dissemination is the haema-
togenous circulation (bloodstream), many tumour cells will travel to their destination 
via the lymphatic system (Van Zijl et al., 2011). Following intravasation, the tumour 
cells need to evade immune detection and subsequent destruction (Valastyan & 
Weinberg, 2011). The majority of tumour cells do not survive this challenge and are 
eliminated before getting to their new site (Valastyan & Weinberg, 2011). Transit of 
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tumour cells through the circulatory system commonly involves formation of tumour 
emboli, consisting of the tumour cell aggregating with platelets and other leucocyte 
cells, which, by default, ‘cloaks’ the tumour cells, and thereby avoids immune sur-
veillance mechanisms (Hart, 2009). If they can adapt to survive within the new envi-
ronment of the circulatory system, the cell must then arrive at its target organ, ex-
travasate back out of the blood vessel and into the new host cellular environment, 
and then persist and eventually re-grow into a tumour, with each of these stages 
being inefficient (Valastyan & Weinberg, 2011).  
The consequent tumour deposit (now termed a micrometastases) can remain 
dormant at this new site until either their growth is triggered, the host environment 
becomes conducive to re-grow, or the angiogenic-switch is triggered (Holmgren et 
al., 1995). The growth environment and suitability relies heavily upon the ‘seed and 
soil’ theory: the principle being that the new ‘host’ tissue must have a permissive 
environment for tumour growth, including an appropriate extracellular matrix, 
growth factors, and supportive cellular network. Therefore, if the new ‘home’ for the 
tumour cells is acceptable, the tumour begins to grow and form a secondary tumour 
(Martin et al., 2013). The eventual site of tumour metastasis is often consequence of 
the location of the primary tumour and its vascular (or lymphatic) drainage. However, 
in several cases this predictable route of dissemination is not straightforward and the 
‘rule’ is disobeyed. One such example is metastasis of lung carcinoma to the brain, 
‘uphill’ from the lungs. The reason for this ‘seed and soil’ theory; discussed above. 
 Despite metastasis being a devastating outcome of cancer, it is now accepted 
that, in many cases, the disseminated tumour cells may lie dormant at their new site 
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for many years which in some cases can actually persist but not cause clinical metas-
tases. In several cases, it is the presence of the metastatic deposit(s) which is de-
tected and confirms the presence of cancer in a patient, in other cases metastatic 
seeding may have occurred several years before diagnosis of a primary tumour. The 
metastatic microenvironment contributes and retards the development and re-
growth of the disseminated tumour, with either progressive genetic aberrations in 
the tumour or perturbations in this cellular ‘host’ environment being the trigger for 
establishment of the clinically evident metastasis. Successful tumour metastasis is 
therefore heavily reliant upon the tumour to adapt and respond to its surroundings 
at each stage of the invasive and metastatic process: the primary tumour site, inva-
sive environment, systemic circulation and the final metastatic location (Valastyan & 
Weinberg, 2011). 
 
I.2.1.4 Reprogramming energy metabolism 
In order to survive and adapt, the tumour must modify and respond to the surround-
ing environment; this includes how it derives energy and utilises the available nutri-
ents to this effect (Zheng, 2012). The metabolic phenotype of cancer cells is compa-
rable to that observed in other rapidly proliferating cell scenarios, with the exception 
that, in cancer, these changes are a consequence of genetic alterations and subse-
quent cell-autonomous signalling, rather than a response to the ‘conventional’ exog-
enous growth factor mediated signalling pathways (Gatenby & Gillies, 2004). In terms 
of metabolic changes, tumour cells demonstrate increased glucose uptake, elevated 
glutamine uptake and enhanced lipid and nucleotide biosynthesis. The high glucose 
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consumption and increased production of lactate by cancer cells, through aerobic 
glycolysis, was identified almost a century ago and is termed the Warburg Effect 
(Vander Heiden et al., 2009). Normally cells generate energy (in the form of adeno-
sine triphosphate, ATP) from glucose by mitochondrial oxidative phosphorylation, 
producing CO2 as an end product. However, energy production in cancer cells occurs 
mainly by aerobic glycolysis of glucose, even when there is sufficient oxygen, and the 
cells have fully functional mitochondria. Relative to oxidative phosphorylation, which 
produces 36 molecules of ATP per molecule of glucose, aerobic glycolysis is an inef-
ficient means of generating ATP, with only 2 molecules of ATP produced per glucose 
molecule. Conversely, the rate of glucose metabolism in aerobic glycolysis is signifi-
cantly greater than in oxidative phosphorylation, with lactate being produced up to 
100 times faster in glycolysis. Subsequently, the two processes counterbalance one 
another and the amount of ATP produced is comparable between oxidative phos-
phorylation and aerobic glycolysis (Zheng, 2012). In light of the poor efficiency of 
aerobic glycosylation, and higher rate of glucose breakdown, tumour cells need to 
uptake a considerably high level of glucose in order to meet their energy require-
ments (Gatenby & Gillies, 2004). Despite the central role for the Warburg effect in 
cancer development, several hypotheses and molecular mechanisms have been pro-
vided for its involvement, but, as yet, no definitive function for the Warburg effect in 
cancer has yet been confirmed. 
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I.2.1.5 Evasion of immune system 
The ability of tumour cells to avoid identification and removal by the immune system 
is now considered a fundamental hallmark of cancer (Hanahan & Weinberg, 2011). 
Since tumour cells are not, in effect, ‘foreign’, the vast majority of cancers avoid im-
munosurveillance and, therefore, naturally evade immune detection (Schreiber et 
al., 2011). Similarly, because tumour cells are fundamentally ‘self’, any autoimmune 
response is, generally speaking, prevented. Of the tumour cells which do raise an 
immune response, they generally are associated with the expression of immunogenic 
tumour antigens (Schreiber et al., 2011); however, several mechanisms have evolved 
to allow tumours to escape immune detection or eradication in this regard. Ulti-
mately, the immune system is ‘tricked’ into failing to detect or recognise tumour 
cells, or to downregulate itself and drop below a level for adequate immune activa-
tion (Schreiber et al., 2011).   
 
I.2.1.6 Enabling characteristics: Genome instability 
The hallmarks of cancer, define the phenotypic attributes of cancer resulting from 
genetic mutations and epigenetic regulation of a range of oncogene and tumour sup-
pressor genes, these are underpinned by an enabling requirement for their appear-
ance. Despite cells throughout the human body being exposed to a panoply of puta-
tive mutagenic factors, the rate and extent of cancer development is significantly 
lower than that predicted by these encounters (Mertz et al., 2017). This is because, 
under normal conditions, cells are well equipped to both detect and repair DNA dam-
age, with severe damage triggering cell removal via initiation of apoptosis (Borges et 
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al., 2008). In contrast, cancer cells are often deficient in a normal DNA repair func-
tion, with this deficiency allowing the tumour to develop genomic instability (Shen, 
2011). In the presence of this deficiency, the tumour cell becomes more susceptible 
to disruption of tumour suppressor genes, generation of oncogenic fusion genes, and 
chromosomal aberrations, which subsequently progress and accelerate the tumour 
towards a more malignant state, thereby enabling development of subsequent can-
cer hallmarks (Sadikovic et al., 2008). 
 
I.2.1.7 Enabling characteristics: Tumour promoting inflammation 
For the success of transition of a cancer cell into a malignant neoplasm the tumour 
microenvironment (TME) plays an important role. The TME is the cellular surround-
ings in which the tumour sits. It is composed of many different types of non-neo-
plastic cells, such as cells of the immune system, fibroblasts and adipocytes. Tumour 
cells as well as immune cells can influence the TME. The TME is constantly changing 
as a result of tissue remodelling, metabolic alterations in the tumour and changes in 
the recruitment of stromal cells including a diversity of immune cells (Swartz et al., 
2012). The TME provides the essential signals that activate the transcription factors 
and therefore it is the stromal or non-malignant cells that induce the requisite tran-
scription programs allowing the necessary mesenchymal phenotypes to invade dis-
tant tissues and establish a new environment (Mbeunkui & Johann, 2009). 
The presence of these tumour-associated cells drives an enabling characteristic of 
cancer. Although inflammation has long been associated with tumour development, 
the involvement and presence of this condition is now believed to be a protective 
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response toward the cancer, which enables malignancy. Commonly an inflammatory 
component is present in the microenvironment of the vast majority of solid malig-
nancies (Grivennikov et al., 2010). This cancer-related inflammation involves cells of 
both the adaptive and innate immune system, including the infiltration of leukocytes, 
predominantly tumour-associated macrophages, and several inflammatory media-
tors, such as tumour necrosis factor-α (TNFα), interleukin-6 (IL-6), and chemokines, 
such as CXCR4 and CXCL12 (Grivennikov et al., 2010).  
The presence of inflammatory cells within a tumour was initially perceived as being 
related to an immune reaction and an attempt by the host to ‘destroy’ the tumour. 
Although this may provide a contribution towards explaining the presence of inflam-
matory cells within the tumour, it is now known that growth factors, chemokines, 
and other cellular mediators can act to promote several tumorigenic processes, such 
as tumour proliferation, the invasive tumour phenotype, angiogenesis and, ulti-
mately, tumour chemotaxis and motility (Raman et al., 2007).  
 
I.2.1.8 Cancer Degradome and Malignancy 
A major defining feature of malignancy is the ability to acquire an improved vascula-
ture system, penetrate into surrounding normal tissues and disseminate to distant 
sites (Martin et al., 2013). Each one of these processes relies heavily upon the in-
creased expression and activity of diverse extracellular endoproteases from multiple 
enzymatic classes, namely the metalloproteases and the serine, threonine, cysteine 
and aspartic proteases. These proteases constitute the cancer degradome—the rep-
ertoire of proteases that cells and tissues coordinately regulate to modulate their 
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local environment (Lopez-Otin & Overall, 2002; Overall & Blobel, 2007). These endo-
proteases are frequently upregulated within tumour tissue where they promote the 
development and expansion of the tumour, formation of new blood vessels to sup-
port the burgeoning energy demands of the rapidly growing tumour and facilitate 
the metastasis of cancer cells to distant organs (Egeblad & Werb, 2002). 
 There is now a considerable body of literature demonstrating elevated ex-
pression of these endoproteases in primary tumours and metastases, with the ma-
jority demonstrating an association with tumour progression or validity as prognostic 
indicators of clinical outcome (Gialeli et al., 2011; Levicar et al., 2003). However, it is 
now deemed oversimplistic to think the function of these proteases is solely to me-
diate tissue destruction and create a path for tumour cell motility and migration, with 
roles for these proteases identified in a broad range of tumorigenic processes (Lopez-
Otin & Matrisian, 2007). These enzymes are known to be central mediators of growth 
factor activation, cellular adhesion, cellular survival and immune surveillance, to 
name a few (Sternlicht & Werb, 2001). Taken together their broad but essential role 
in tumorigenesis and their relationship to disease prognosis, these enzymes can be 
defined as a significant force in the phenotypic evolution of cancer (Martin et al., 
2013). 
 
 I.3 Matrix Metalloproteinases 
It has long been recognized that cancer invasiveness and dissemination to distant 
organ sites involves the action of many different extracellular proteases, but partic-
ularly the matrix metalloproteinases (MMPs) (Egeblad & Werb, 2002). The MMPs are 
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a member of the large protease metzincin superfamily, alongside the ADAMS (a dis-
integrin and metalloproteinase) and the ADAMTS (a disintegrin and metalloprotein-
ase with thrombospondin motif) (Malemud, 2006). The MMPs are themselves a fam-
ily of at least 24 human proteolytic enzymes that are responsible for degrading a 
range of extracellular matrix proteins (Roy et al., 2009), contributing to the formation 
of a microenvironment permissive of tumour survival, growth, expansion and metas-
tasis. They are divided into eight distinct groups; five are secreted and three are 
membrane-bound (membrane-type matrix metalloproteinases, MT-MMPs) based on 
both their substrate specificity and the arrangement of their protein domains (Roy et 
al., 2009). The majority of MMPs, with the exception of the MT-MMPs and MMP-11, 
-21, -23 and -28, are secreted by the cell as inactive zymogens and require activation 
extracellularly by cleavage of the N-terminal pro-domain resulting in a fully functional 
enzyme (Kessenbrock et al., 2010). In contrast, the MT-MMP family is not secreted 
from the cell but is activated intracellularly and presented on the cell surface in a 
proteolytically active state (Reunanen & Kahari, 2013).  
 Structurally the MMPs comprise of a common arrangement of four key struc-
tures; firstly, the pro-peptide which consists of 80 amino acids to sustain the MMP in 
the latent form (Clark et al., 2008). Secondly, the catalytic domain exhibiting the con-
served HEXGHXXGXXH zinc-binding sequence characteristic of the metzincin super-
family of proteinases, followed by an invariant methionine which is involved in a 
structural feature called the Met-turn which mediates enzyme activity (Clark et al., 
2008). Thirdly, there is the presence of the haemopexin (Hpx) domain, which pro-
vides substrate specificity to the MMP. These three central structures are all con-
nected by a linker region of varying length (Osada et al., 2004). As with all protein 
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families, exceptions to this architecture do exist with MMPs, for instance MMP-7, 
MMP-23 and MMP-26 all lack the Hpx and linker domain, suggesting different prote-
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Structural class MMP 
number 















8 Neutrophil collagenase, Colla-
genase-2 
10 Stromelysin-2 
12 Macrophage elastase 
13 Collagenase-3 
18 Collagenase-4 





Gelatin-Binding 2 72kDa Type IV gelatinase, 
Gelatinase A 
Fibronectin type ΙΙ 
repeats 
9 92kDa Type IV gelatinase, Gelati-
nase B 
Minimal Domain 7 Matrilysin No C-terminal 
hemopexin do-
main; no hinge re-
gion 
26 Endometase, matrilyson-2 
Furin-Activated 
and Secreted 





21 MMP-23A  
Type I Trans-
membrane 
14 MT1-MMP Transmembrane 
domain; cytoplas-








23 Cystein array MMP No C-terminal 
hemopexin do-
main; no hinge re-
gion 





Table I.1 Classification of the human MMPs.  Adapted from Curran and Murray (2000) 
and Egebald and Werb (2002). 
 
 
MMPs are expressed by the cell as inactive zymogens (proMMPs), this inactivation is 
caused by the interaction of a cysteine residue of the pro-domain with the zinc ion 
of the catalytic site (Egeblad & Werb, 2002; Kessenbrock et al., 2010). They are inac-
tive until they are required for any one of several processes they stimulate (eg. angi-
ogenesis, morphogenesis), wherein they are activated extracellularly via proteolytic 
removal (by proteolytic enzymes dependant upon the MMP; for example serine pro-
teases and furin) of the pro-domain which opens up the active centre of the MMP 
molecule and allows the MMP to bind to its protein substrate(s) (Sternlicht & Werb, 
2001). 
 
I.3.1 Function of MMPs 
MMPs regulate many normal physiological processes including tissue growth and 
embryogenesis (Brown, 1997) and they are secreted to catalyse the degradation of 
the ECM proteins such as collagen and gelatin as well disrupt the contact between 
cells (Bourboulia & Stetler-Stevenson, 2010). During malignant cell migration the 
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MMPs are involved in many processes, including removing sites of adhesion, cleaving 
cell-cell or cell-matrix receptors and releasing chemo-attractants from the ECM, thus 
participating in several pertinent processes associated with cancer,  such as innate 
and adaptive immunity, inflammation, angiogenesis, bone remodelling, and neurite 
growth (Rundhaug, 2003; Loffek et al., 2011).  
  The controlled cleavage of malignant factors by different MMPs also is a ma-
jor player in modulation of different cell signalling events, such as the ECM-tethered 
VEGF, which directs the specific binding pattern of VEGF to ECM components guiding 
the invading endothelial cells and supporting the process of neo-angiogenesis 
(Deryugina & Quigley, 2015). The ECM-tethered VEGF is inactive in complex with con-
nective tissue growth factor (CTGF), but becomes active after proteolytic cleavage of 
CTGF by MT1-MMP, MMP-1, -3 and -13. In contrast, the cleavage of VEGF by MMP-
3 and -9 generates a shorter, non-heparin binding active form of VEGF that subse-
quently induces irregular vessel sprouting (Lee et al., 2005). 
 
I.3.2 Regulation of MMPs 
Under normal physiological conditions, the activities of MMPs are precisely regulated 
at the level of transcription, activation of the precursor zymogens, interaction with 
specific ECM components, and inhibition by endogenous inhibitors (Visse & Nagase, 
2003). At a local level, MMP activity is further regulated by interaction with four spe-
cific exogenous protease inhibitors, termed tissue inhibitor of metalloproteinases 
(TIMPs 1-4), with a broad inhibitory specificity and combined ability to inhibit all the 
MMPs (Nagase et al., 2006; Brew & Nagase, 2000; Batra et al., 2012). TIMPs, similarly 
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to MMPs, are regulated at the transcriptional level by many cytokines, growth factors 
and chemokines (Clark et al., 2008). Disequilibrium of the MMPs and TIMPs balance 
is associated with many diseases including cardiovascular diseases and cancers 
(Snoek-van Beurden & Von den Hoff, 2005; Jackson et al., 2017). Several studies have 
shown a role for the TIMPs in the vast majority of cancer hallmarks, with TIMP 
dysregulation evident in the tumour mass of the microenvironment and TIMP1 over-
expression or TIMP3 silencing commonly related to a poor prognosis (Jackson et al., 
2017). In NSCLC, TIMP1 and TIMP2 levels are higher in adenocarcinomas compared 
to squamous cell carcinomas, whereas the converse is apparent for TIMP3 (Hida & 
Hamada, 2012). This indicates potential different involvements of MMPs (and TIMPs) 
between NSCLC sub-types, with significant implications for diagnostic and therapeu-
tic approaches.   
 Despite the ‘conventional’ function of TIMPs as endogenous inhibitors of 
MMPs, recent studies have now identified TIMPs also have the ability to directly in-
fluence cellular physiology as well as disease progression without an involvement of 
MMPs (Stetler-Stevenson & Gavil, 2014), strongly supporting TIMPs as important fac-
tors for a number of reasons (Jackson et al., 2017). 
 
I.3.3 Role of MMPs in wound healing 
MMPs play a role in the different stages of wound healing; they are involved in the 
breakdown of the damaged ECM in wounds, specifically migration of cells to close 
the wound and angiogenesis to facilitate cell survival and nutrition (Caley et al., 
2015). In terms of re-vascularisation of the repairing wound, MMPs degrade the ECM 
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and basement membrane around the capillaries and allow endothelial cells to mi-
grate from capillaries near the wound and establishment of new blood vessels into 
the wound bed through angiogenesis (Gill & Parks, 2008). Conversely, as well as de-
grading proteins to facilitate angiogenesis, certain MMPs (e.g. MMP-1, -3, -9 and -
10) can also function to retard angiogenesis and play a role in vascular collapse, 
(Loffek et al., 2011; Chen et al., 2013). In this context, activated forms of these pro-
teinases promote degradation of collagen type I, or basement membrane matrices 
that represent other important angiogenic substrates,  supporting the hypothesis 
that proteolytic ECM degradation, or destruction of the angiogenic scaffold also leads 
to collapse of angiogenic networks as well as development of new ones (Saunders et 
al., 2005).  
 
I.3.5 MMPs in cancer 
Under normal physiological conditions MMPs activity is tightly regulated, however 
when unregulated or dysfunctional they contribute to a diverse range of degradative 
diseases such as arthritis, cardiovascular disease and cancer (Nagase et al., 2006; 
Clark et al., 2008). During tumorigenesis the MMPs are selectively activated and se-
creted into the local tumour microenvironment, with an involvement in all of the 
‘hallmarks of cancer’ (Kessenbrock et al., 2010). Subsequently, because MMPs are 
centrally involved in cell migration, growth factor regulation, tissue remodelling, and 
degradation of the extracellular matrix, they are major drivers of tumour progression 
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if deregulated (Overall & Kleifeld, 2006).  Consequently, the extracellular microenvi-
ronment is an integral and dynamic scaffold that dictates cell function and cell fate 
for both normal and cancer cells (Zhang et al., 2014).  
 MMPs have been found to be up-regulated in many cancer types, making 
them a very important target for diagnosis, prognosis and therapy (Coussens et al., 
2002; Overall & Kleifeld, 2006; Roy et al., 2009). In pathological conditions such as 
cancer the equilibrium that is created between the MMPs and the three control 
states (activation of the zymogens, transcription, and inhibition of the active forms), 
is shifted toward increased MMP activity leading to tissue degradation (Verma & 
Hansch, 2007). For instance, cancers whereby MMPs have been up-regulated in-
clude; MMP-9 in breast cancer (Wu et al., 2008), MMP-2 in pancreatic cancer (Yoko-
yama et al., 2002) and MMP-10 and MMP-14 in lung cancer (Gill et al., 2004; Atkinson 
et al., 2007), amongst many others. These concerted activities subsequently provide 
the foundations to the many steps of remodelling and cellular rearrangements asso-
ciated with tumour invasion, and ultimately metastasis.  
 
I.3.5.1 Involvement of MMPs in establishment of pre-metastatic niche 
 In addition to the ‘conventional’ role for MMPs in modulation of the ECM and 
proteins within the tumour microenvironment, to permit cellular motility and inva-
sion, they are also now known to play a role in ‘establishing the premetastatic niche’ 
(Shuman Moss et al., 2012). The premetastatic niche being the readying of the area 
in which a secondary tumour will establish and develop, a process involving many 
signals including VEGF, transforming growth factor β (TGFβ), tumour necrosis factor 
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α (TNFα) and specific chemokine proteins (Kaplan et al., 2006). MMPs are also acti-
vated at these distance sites, with roles involved in regulation of these cellular factors 
and cellular reorganisation permissive of focused and directed metastasis of the can-
cer cells and provision of the appropriate ‘soil’ for the cancer ‘seed’ (Shuman Moss 
et al., 2012), although the specific mechanisms need to be further explored.  
 
I.3.5.2 Pro- and anti-tumorigenic role of MMPs  
 Further to the general involvement of MMPs in tumorigenesis, individual 
MMPs are shown to have different roles during cancer progression (Gialeli et al., 
2011). For instance, elevated MMP-2 levels is associated with driving tumour inva-
sion and metastasis (Kessenbrock et al., 2010), whereas MMP-8 over expression pro-
vides a protective effect in the metastatic process, decreasing the metastatic poten-
tial of breast cancer cells (Gialeli et al., 2011). Similarly, MMPs with high proteolytic 
homology and similar peptide selectivities have also been shown to demonstrate ei-
ther comparable activities in different tumour types, or different roles in the same 
tumour subtype (Al-Alem & Curry, 2015). For example, MMP-10 and MMP-3 are 
highly homologous MMPs within the stromelysin sub-class, but show different tu-
mour expression and activities. In breast cancer MMP-10 is downregulated, however 
MMP-3 showed no differential expression (Benson et al., 2013). Furthermore, an 
MMP can also have contradicting activities within the same tumour, both temporally 
and geographically, such as MMP-10 and MMP-3 show strong expression in NSCLC, 
MMP-10 over expression is localised to the tumour mass as opposed to the stroma, 
indicating its role in the early stages of tumour development, as opposed to MMP-3 
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where its strong expression in NSCLC is observed in the tumour stroma, indicating it 
plays a role in local growth of the tumour (Al-Alem & Curry, 2015; Gill  et al., 2004). 
 The dichotomy of activities for the MMPs as being both pro- and anti-tumor-
igenic necessitates elucidation of the individual role of MMPs in tumour evolution, in 
order to identify and validate their role as diagnostic markers and whether they are 
targets or anti-targets for therapeutic exploitation (Overall & Kleifeld, 2006; Cathcart 
et al., 2015; Bonfil et al., 2008). 
 
I.3.7 Role of MMP-10 in Tumorigenesis  
One MMP for which information is limited is MMP-10, also known as stromelysin-2, 
which reportedly plays a role in vascular remodelling, wound healing and skeletal 
development (Batra et al., 2012). With regards to cancer, increased MMP-10 expres-
sion has been demonstrated in carcinomas of several human tissues (Tsang et al., 
2012; Aung et al., 2006), including head and neck cancer (Deraz et al., 2011; Tsang et 
al., 2012), gastric cancer (Aung et al., 2006), bladder cancer (Seargent et al., 2005) 
and non-small cell lung cancer (NSCLC) (Gill et al., 2004). This expression, particularly 
in the case of NSCLC, related to altered function as exemplified by significantly higher 
levels of proteolytically active MMP-10 in NSCLC relative to the corresponding histo-
logically normal lung tissue (Gill et al., 2004). Furthermore, MMP-10 expression in 
NSCLC is independent of tumour grade, stage, histological type, or lymph node status 
(Gill et al., 2004). However, elevated levels of MMP-10 are observed in recurrent 
NSCLC (Cho et al., 2004), which together suggests a lack of association of this MMP 
with the invasion or metastatic process (Gill et al., 2004). This is further supported by 
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the fact that MMP-10 is also not related to the invasive phenotype of skin cancer 
(Kerkela et al., 2001), or to increased pathological stage in bladder cancer (Seargent 
et al., 2005). Together these studies indicate a putative role for this MMP in the ear-
lier stages of tumour development, rather than invasion and metastasis associated 
with many other MMP (Miyata et al., 2007). This hypothesis is supported by studies 
within this research group, wherein overexpression of MMP-10 in a human NSCLC 
tumour model did not affect cellular proliferation in vitro, but caused significant re-
tardation of tumour growth in vivo (personal communication by Gill, Figure I.3). 
 


























Figure I.3: Growth of MMP-10 expressing NSCLC cells in vivo 
NSCLC H460 cells stably expressing MMP-10 were introduced sub-cuta-
neously into nude mice and tumour growth was determined over time.  
MMP-10 expressing tumour (clone 1 and 2) growth was significantly re-
tarded relative to mock transfected cell controls.  
The degree of growth retardation is relative to level of MMP-10 selec-
tive substrate cleavage. Clones 1 and 2 demonstrate 2.5 and 4.0 fold 
greater MMP-10 activity than control cells, respectively 
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MMP-10, unlike the majority of MMPs, localises to the tumour cells rather than the 
supporting stromal cells within the tumour microenvironment (Gill et al, 2004; Sear-
gent et al., 2005). The enzyme is secreted from these cells into the extracellular fluid 
as an inactivate 57kDa proenzyme, wherein it is converted into the 44kDa active en-
zyme by a cascade involving several proteases, including kallikreins, cathepsins, and 
other MMPs (Saunders et al., 2005). Once activated, MMP-10 continues the progres-
sive proteolytic cascade through activation of pro-MMP-1, -7, -8, -9, -13, broadening 
the combined ability of these enzymes to restructure the tumour microenvironment 
(Zhang et al., 2014; Davis & Saunders, 2006).  
 The heightened concentration of MMP-10 in tumours is thought to be re-
quired for the restructuring of the endothelial cells during tumour angiogenesis 
(Saunders et al., 2005). MMP-10 has relatively broad substrate specificity (Zhang et 
al., 2007) with the ability to degrade a variety of extracellular matrix proteins, includ-
ing collagen III-V and fibronectin (Batra et al., 2012). MMP-10 has been found to play 
a role in the capillary tube regression response, it causes regression of endothelial 
cells; they deconstruct the ECM scaffold in which the newly formed vascular network 
is embedded (Davis & Saunders, 2006). The MMP-10-mediated activation of MMP-1 
has been found to cause consequent acceleration of capillary tube regression of ECs 
in vitro, further supporting an involvement for MMP-10 in tumour establishment ra-
ther than the invasive phenotype (Chang et al., 2006). Consequently, with MMP-10 
being involved in vascular reconstruction, and its relationship to several cancer types, 
modulation of its expression and activity may function to prevent vascular stability 
occurring and thus interference of tumour establishment and survival. 
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I.3.6 Modulation of MMP activity as a therapeutic target 
With MMPs being up-regulated in many cancers and several being pro-angiogenic, 
targeting these is hypothesised as a therapeutic target. Development of chemical in-
hibitors of MMP activity (MMP inhibitors; MMPi) has been a source of therapeutic 
activity for many years (Fisher & Mobashery, 2006). Initial MMPi’s demonstrated dis-
appointing results, due to lack of specificity and dose-limiting off-target toxicities in 
the clinic (Coussens et al., 2002; Fisher & Mobashery, 2006). Furthermore, lack of 
success was also attributed to poor appreciation of the pathophysiology of MMPs 
and inappropriate clinical trials, in which the compounds were evaluated against late 
stage cancers after MMP-dependent invasion and metastasis. For instance, one of 
the first MMPis evaluated in cancer patients was Batimastat, administered for the 
use of malignant effusions (Macaulay et al., 1999). Although highly potent against 
several MMPs (MMP-1, -2, -3, -7, -9 and -14) and showing clinical efficacy against 
malignant pleural effusion, trials were ceased due to its poor solubility and limited 
pharmacokinetics and the advent of MMPi with improved bioavailability such as 
Marimastat (Cathcart et al., 2015). However, this MMPi was found to cause signifi-
cant musculoskeletal pain and inflammation, with trials stopped because they did 
not produce significant results in terms of symptomatic progression or overall sur-
vival (Cathcart et al., 2015).  
 Advances have been made in this area in recent years through greater under-
standing of these complex proteins, yielding new generations of MMPis to be de-
signed (Overall & Lopez-Otin, 2002; Hu et al., 2007; Van Themsche et al., 2004; 
Cathcart et al., 2015). Those with selective targeting towards specific MMPs offering 
a more promising outcome in reflection to the realisation that some MMPs are anti-
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angiogenic, so targeting these in some cancers would have a counterproductive ef-
fect (Decock et al., 2011). 
 There are now several alternative therapeutic strategies hypothesised for 
modulation of MMPs, including MMP-selective antibodies (Nam et al., 2012). One 
such antibody is DX-2400, a MMP-14 specific inhibitor which blocks substrate access 
but does not chelate or interact with the catalytic zinc (Cathcart et al, 2015). Studies 
to date of DX-2400 indicate this antibody is selective for MMP-14 over other MMPs 
(Devy et al., 2007). In preclinical studies DX2400 prevented metastases and signifi-
cantly decreased tumour mass (Devy et al., 2009). Similarly, the MMP-9 inhibitory 
antibody REGA-3G12, can differentiate between MMP-9 and its close homologue 
MMP-2, has shown indicative potential for therapeutic exploitation (Cathcart et al., 
2015). However, these antibodies have not yet been evaluated in the clinic. 
 Another approach currently in its infancy is the inhibition of MMP expression 
at the transcription or translational level, rather than targeting blockade of enzyme 
activity post-translationally (Cathcart et al., 2015). This strategy relies on an appreci-
ation and understanding of the upstream signalling pathways and control mecha-
nisms responsible for expression of MMPs. In this context, several pathways have 
now been related to MMP expression, such as NK-kappaB, p38 and Jun-N-terminal 
kinases (JNK), and studies are now beginning to identify and characterise these con-
trol mechanisms (Gordon et al., 2009). However, no studies in this area have yet been 
evaluated in vivo or clinically.  
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I.4 Epigenetic control of gene expression 
Genetic expression in addition to being controlled by the DNA sequence, and subse-
quent transcription, and translation, is also regulated by epigenetic factors (Goll & 
Bestor, 2005; Goldberg et al., 2007). Epigenetics refers to heritable changes in gene 
expression determined by factors other than alteration of the primary DNA sequence 
(Goldberg et al., 2007). Through modification of these non-genetic factors, gene tran-
scription can be regulated allowing the temporal and spatial expression of genes 
(Goldberg et al., 2007). Epigenetic regulation is largely controlled by two processes, 
alteration in chromatin structure to regulate ‘entry’ of the transcriptional machinery 
to the DNA (post-translational modification of histones), and direct epigenetic mod-
ification of DNA through methylation of specific nucleotides (DNA methylation). 
 
I.4.1 Promoter methylation 
 In the promoter regions of genes, methylation occurs at dinucleotides com-
prising cytosines located prior to guanosine in the linear sequence of DNA bases. Re-
gions of the genome with a high density of CpGs are termed CpG islands, with DNA 
methylation of these islands correlating with transcriptional repression and gene si-
lencing (Robertson & Jones, 2000). This mode of silencing gene expression is essen-
tial to several ‘normal’ long-term processes, such as inactivation of the X-chromo-
some, and genomic imprinting, and is a central mechanism in the regulation of cellu-
lar differentiation and ultimately cell identify and fate (Robertson & Jones, 2000). In 
cancer there is global genome-wide hypomethylation, accompanied by hypermeth-
ylation of CpG islands in the promoter region of many genes commonly involved with 
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loss of tumour suppressor function. A central role for DNA methylation as an onco-
genic factor is reinforced by the induction of growth arrest and cell death in haema-
tological malignancies following exposure to inhibitors of DNA methyltransferases 
(azacitadine and decitabine) (Robertson & Jones, 2000). 
 
I.4.2 Epigenetic modification of histones 
 In terms of histone modifications, DNA is wrapped around histone octamers 
(composed of four core histones H3, H4, H2A and H2B, organized into two dimers, 
H3-H4 and H2A-H2B)  to form nucleosomes, these nucleosomes are the fundamental 
units to chromatin (Luger et al., 1997). The positively charged histones interact with 
the negatively charged DNA (due to phosphate groups) by electrostatic interactions, 
resulting in nucleosomal compaction (figure 1.4). Ultimately, in combination with 
short linker DNA sequences, these long chains of tightly compacted nucleosomes 
(‘beads on a string’) form chromatin and ultimately chromosomes (Annunziato, 
2008). The degree to which the nucleosome aggregates are compacted (or relaxed) 
dictates transcriptional activity, causing expression or repression of specific genes. 
Essentially, tightly compacted nucleosomes cause “closed chromatin” (Heterochro-
matin) and subsequent transcriptional repression, whereas an “open” chromatin 
structure (Euchromatin) is characteristically transcriptionally active (Phillips & Shaw, 
2008).     
 




Figure I.4 Histones are proteins around which DNA can wind for compaction and gene 
regulation. The conformation of the histones can be altered with binding of different 
epigenetic factors to the histone ‘tails’, this opens up the DNA region where tran-
scription machinery proteins; transcription factors and co-activators bind to turn on 
gene transcription. Removal of these factors from the histone tails via methylation, 
or deacetylation condenses DNA around histones and thus, make DNA unavailable 
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Modulation of nucleosomes, to facilitate active gene transcription, is controlled by 
promoting or inhibiting condensation of the DNA-histone complex, a process medi-
ated predominantly by post-translational modifications of the N-terminal tails of the 
histone proteins, including methylation, acetylation, and phosphorylation, amongst 
others (Garcia et al., 2007). These changes can affect gene expression by allowing or 
restricting the accessibility that the transcription factors (TFs) has to the DNA (Ban-
nister & Kouzarides, 2011). Transcriptional co-regulators play an important role in 
epigenetic regulation by recruiting chromatin-modifying enzymes. These co-factors 
bind to the TFs which are recruited to the regulatory region of genes, controlling their 
transcriptional activation or repression (Mottis et al., 2013). 
 
Figure I.5 The dynamic state of histone acetylation/deacetylation regulated by HAT 
and HDAC enzymes. Acetylation of histones alters accessibility of chromatin and al-
lows DNA binding proteins to interact with exposed sites to activate gene transcrip-
tion. Deacetylation has opposing effects to the HATs, closing off access to chromatin 
and repressing gene transcription [adapted from Rodd et al., 2012]. 
 
 
The epigenetic control of gene expression, particularly through modification of his-
tone conformation, is now known to be central to the control of tumorigenesis, with 
many tumours exhibiting histone modifications; including NSCLC (Chervona & Costa, 
HDAC 
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2012). In terms of the hallmarks of cancer, there is growing evidence to support post-
translational modifications of histones in the regulation of many of the hallmarks, 
including as drivers of invasion and metastasis. Furthermore, there is now compelling 
evidence to support a function for the enzymes responsible for histone modifications 
on a whole range of non-histone proteins. In many cases these proteins targeted by 
acetylation are the products of oncogenes or tumour suppressor genes phosphory-
lation and methylation, documented in several types of cancers (Singh et al., 2010; 
Muthusamy et al., 2010; Kanwal & Gupta, 2012). 
 
1.4.1 Histone deacetylase (HDAC) 
The most common post-translational histone modification is acetylation (Bannister 
& Kouzarides, 2011; Turner, 2000). Acetylation and deacetylation of both histone and 
non-histone proteins is regulated by the histone acetyl-transferases (HATs) and his-
tone deacetylases (HDACs) classes of regulatory enzymes (Petta et al., 2013). HATs 
attach acetyl groups onto the lysine amino acids of target proteins; with the HDACs 
having opposing effects to the HATs and removing the acetyl groups from a ɛ-N-ace-
tyl lysine amino acid, particularly on histones central to epigenetic control of gene 
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Class HDAC enzymes Cellular localisation 
Class I HDAC1 Nucleus 
 HDAC2 Nucleus 
 HDAC3 Nucleus and Cytoplasm 
 HDAC8 Nucleus 
Class IIa HDAC4 Nucleus and Cytoplasm 
 HDAC5 Nucleus and Cytoplasm 
 HDAC7 Nucleus and Cytoplasm 
 HDAC9 Nucleus and Cytoplasm 
Class IIb HDAC6 Cytoplasm 
 HDAC10 Cytoplasm 
Class IV HDAC11 Nucleus and Cytoplasm 
 
Table I.2 Classification of the classic zinc-dependant histone deacetylases (HDACs) 
[Adapted from Mohseni et al., 2013]. 
 
 
 HDACs form part of the classical HDAC superfamily, constituting five groups 
based on their sequence similarity and function (West & Johnstone, 2014). Class I is 
comprised of HDAC1, 2, 3 and 8, all of which have the simplest structure; class IIa 
includes HDAC4, 5, 7 and 9, which have large N-terminal extensions; class IIb consists 
of HDAC6 and 10, with extended C-termini; and class IV includes a single member, 
HDAC11 (Livyatan & Meshorer, 2013; West & Johnstone, 2014). In contrast, the class 
III sub-family comprises the Sirtuins (SIRT1–7), which although share features with 
both class I and class II HDAC enzymes, are a distinct family that are NAD+ dependent 
rather than being zinc-mediated modulatory enzymes (de Ruijter et al., 2003). In this 
context, the sirtuins are normally not included when describing HDACs. Within the 
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HDAC family, differences exist between to defined classes, with class I HDACs being 
expressed predominantly in the nucleus, and class II HDACs shuttling between the 
cytoplasm and the nucleus (Chang et al., 2006). The differential is now believed to be 
associated with different roles and functions of the HDACs, with class I responsible 
for acetylation of histones and class II playing a role in regulation of non-nuclear 
HDAC targets (de Ruijter et al., 2003). 
 
  
1.4.2 Class I Histone deacetylases 
The class I HDAC family consists of HDAC1, 2, 3 and 8, and localized predominantly 
to the nucleus with high enzymatic activity toward histone substrates, as shown in 
table I.2 (de Ruijter et al., 2003). Class I HDACs remove the acetyl groups from a ɛ-N-
acetyl lysine amino acid on histone tails inducing chromatin condensation, by creat-
ing a non-permissive chromatin conformation and gene transcriptional repression 
(Barneda-Zahonero  & Parra, 2012; Glozak & Seto, 2007). This balance between acet-
ylation and de-acetylation of histones is an important regulatory role of gene tran-
scription in cells, with hypoacetylation resulting in a decrease in the space between 
the nucleosome and the DNA, diminishing accessibility for transcription factors, lead-
ing to transcriptional repression (de Ruijter et al., 2003). 
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1.4.3 Class II Histone deacetylases 
The class IIa HDACs consist of HDAC4, -5, -7 and -9, as shown in table I.2. In contrast 
to class I, these HDACs are expressed in a tissue-specific manner (Lakshmaiah et al., 
2014) and they contain both a nuclear localization signal (NLS) and a nuclear export 
signal (NES) in their structure, aiding nucleoplasmic shuttling of these enzymes 
(Livyatan & Meshorer, 2013). The phosphorylation of the amino termini of class II 
HDACs by calcium/calmodulin-dependent kinase (CaMK) and protein kinase D (PKD), 
creating docking sites for the 14-3-3 family of chaperone proteins, promotes shut-
tling of these HDACs between nucleus and cytoplasm (Chang et al., 2006). Further-
more, the class IIa HDACs exhibit low deacetylase activity towards histones, and pref-
erentially target non-histone proteins, with many of these protein targets involved 
in regulation of gene expression, cell proliferation, migration and death pathways, 
including p53, E2F and MyoD (Dokmanovic et al., 2007; de Ruijter et al., 2003; Gao 
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Figure I.6 Localisation of the class I HDACs versus class II HDACs. Class I HDACs are 
localised to the nucleus of the cell where they are known to deacetylate histones. 
Class II HDACs can shuttle between the nucleus and the cytoplasm of the cell, they 
are known to have low deacetylase activity, so are thought to work on non-histone 
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I.4.4 Pertubation of HDAC expression and activity in cancer 
Cancer is linked to histone hypoacetylation, due largely to overexpression of class I 
HDACs, a factor resulting in several of these enzymes being classified as oncogenes. 
Abnormal expression of many HDACs is associated with numerous cancers (Barneda-
Zahonero & Parra, 2012), for example HDAC1 has been found to be overexpressed in 
colon (Wilson et al., 2006), breast (Zhang et al., 2005), prostate (Halkidou et al., 2004) 
and gastric (Choi et al., 2001) cancers.  Similarly, the class I HDAC; HDAC2 has been 
found to be overexpressed in gastric (Song et al., 2005) and cervical (Huang et al., 
2005) cancers. Other HDACs, respectively class I; HDAC3 and class IIb; HDAC6 have 
been reported to be over expressed in colon and breast cancers (Ropero & Esteller, 
2007). With regards the molecular association between HDAC overexpression and 
tumorigenesis, removal of acetyl groups from histones (by class I HDACs) leads to 
repression of several tumour suppressor genes, such as the cell cycle regulator locus 
CDKN2A (including p16INK4A and p14ARF) and the DNA repair gene, BRCA1 (Tan et al., 
2004). Loss of these tumour suppressor genes such as BRCA1, increases genomic in-
stability (cancer hallmark) because of the failure of these DNA repair pathways (Zam-
borszky et al., 2017).  
 However, conversely to HDAC overexpression, there are now studies showing 
some cancers exhibit a reduction in expression of HDACs which is associated with a 
poor prognosis in patients (Osada et al., 2004; Weichert, 2009) because downregu-
lation or deletion of HDACs may play a role in cancer progression (West & Johnstone, 
2014). For instance, HDAC7 expression is decreased in lung cancer (Osada et al., 
2004), HDAC3 has found to be decreased in cancer of the liver and HDAC4 is routinely 
decreased in gastric tumours (West & Johnstone, 2014). HDAC1 somatic mutations 
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were detected in approximately 8% of dedifferentiated human liposarcomas (Taylor 
et al., 2011), and a frame-shift mutation causing dysfunctional HDAC2 expression was 
observed in human epithelial cancers with microsatellite instability (Ropero et al., 
2006). Together these data suggest a putative tumour suppressor role for some 
HDACs (West & Johnstone, 2014). 
 This association between HDACs and cancer, coupled to the potential targeta-
bility of these enzymes, led to significant efforts to develop therapeutic inhibitors 
with the objective of restoring the histone acetylation balance and inhibition of can-
cer growth (Richon, 2006; Greshock et al., 2008). To date, four HDAC inhibitors (Vo-
rinostat, Romidepsin, Bellinostat, Panobinostat) have been approved for cancer 
treatment, specifically lymphomas and myelomas (West & Johnstone, 2014). From a 
molecular perspective, HDAC inhibition modulates and impinges upon many tumor-
igenic characteristics (hallmarks of cancer), including proliferative capacity, response 
to cell death signalling, angiogenesis, and immune evasion. 
 
I.4.5 Role of class IIa HDAC7 in cancer 
Despite significant interest in the class I HDACs and cancer, very little is known re-
garding class II HDACs. For instance, there is now a strong implication for an involve-
ment of the class IIa member histone deacetylase 7 (HDAC7) in regulation of vascu-
lature structure, and thus by default angiogenesis, a cancer hallmark (Chang et al., 
2006). HDAC7, is expressed within the developing vascular endothelium (Chang et 
al., 2006) and plays a central role in regulating blood vessel structure and organisa-
tion (Ha et al., 2008). Within blood vessels, vascular integrity is regulated by tight 
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junctions between neighbouring endothelial cells (ECs), which form the inner lining 
of the blood vessels (Chang et al., 2006). The maintenance of blood vessel structure 
and integrity mediated by HDAC7 is shown to involve modulation of the expression 
and function of factors involved with endothelial cell morphology, cell-cell attach-
ments, and subsequent vessel formation (Ha et al., 2008). HDAC7 has also been 
found to be involved in the initiation of tumour development with it potentially play-
ing a role in tumour angiogenesis (Zhu et al., 2011). Hypoxia-inducible factor (HIF)-
1∝ is a transcription factor that controls expression of genes responsive to low oxy-
gen tension, including vascular endothelial growth factor (VEGF), which is released 
for blood vessel formation (Kato et al., 2004). The inhibitory domain of HIF-1∝ 
strongly interacts with the C-terminal domain of HDAC7 (Kato et al., 2004). HDAC7 
has also been linked to the regulation of MMP-10 in NSCLC, strongly suggested its 
role in tumour angiogenesis (hallmark of cancer) (Zhu et al., 2011). 
 
I.4.6 HDAC7 and MMP-10 
 The involvement of HDAC7 in vasculature integrity is strongly linked to the 
activity of MMP-10. In terms of a link between HDAC7 and MMP-10, as previously 
discussed, MMP-10 expression has been shown to be repressed in vivo by the activity 
of HDAC7 (Chang et al., 2006), an association supported by the dramatic upregulation 
of MMP-10 expression in the developing vascular endothelium of HDAC7 mutant 
mouse embryos (Chang et al., 2006). Silencing of HDAC7 in endothelial cells resulted 
in alteration of their morphology, motility and led to an inability to form tube struc-
tures, an outcome mediated by proliferation or apoptosis of the endothelial cells 
68 | P a g e  
 
(Mottet et al., 2007), an observation in agreement with the involvement of MMP-10 
(Chang et al., 2006; Mottet et al., 2007). In addition, HDAC7 angiogenic activity and 
modulation of MMP-10 activity has been shown to be regulated by VEGF signalling 
(Ha et al., 2008). Taken together, this strongly suggests that HDAC7 expression and 
activity controls MMP-10 expression and activity, offering a relationship between 



































Figure I.7 A model for modulation of MMPs by HDAC7 through inhibition of MEF2 
activity. MMP-10 expression is controlled by MEF2, which is antagonized by HDAC7 
in ECs. In the absence of HDAC7, MMP-10 is overexpressed and vascular integrity is 
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In regards molecular pathways involved in HDAC7 activity and potentially MMP-10, 
HDAC7 is known to control myocyte enhancer factor-2 (MEF2), a transcription factor 
involved in EC differentiation, by inhibiting its transcriptional regular region; MADS 
(MCM1-agamous deficiens-serum response factor) region through the N-terminal of 
HDAC7 (Dressel et al., 2001). Simultaneously, it is known that MMP-10 is a direct 
target of MEF2, further supporting a relationship that exists between HDAC7 and 
MMP-10 (Chang et al., 2006). Mechanistically, HDAC7 undergoes nucleocytoplasmic 
shuttling (Fischle et al., 2001), allowing HDAC7 to prevent MEF2-mediated transcrip-
tion (Chang et al., 2006). This repressive activity of HDAC7 upon MEF2 in addition to 
being facilitated by nucleocytoplasmic is further controlled by its phosphorylation-
dependent association with the intracellular 14-3-3 proteins. Phosphorylation of con-
served residues in the N-terminal regions of HDAC7 in response to cellular signals 
leads to interaction with 14-3-3 proteins, dissociation of the HDAC7-MEF2 complex, 
and a conformational change culminating in export from the nucleus (Parra et al., 
2005). VEGF has been found to stimulate HDAC7 causing cytoplasmic accumulation 
of HDAC7 in the endothelial cells (ECs), by activating PKD1-mediated phosphorylation 
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Figure I.8 Potential mechanism by which HDAC7 regulates MMP-10 gene expression. 
VEGF stimulated HDAC7 phosphorylation and nuclear export in endothelial cells 
though a VEGF receptor 2-phospholipase Cγ-protein kinase C-PKD-dependent path-
way. The PKD-HDAC7 pathway mediated transcription factor; myocyte enhancer fac-
tor-2 transcriptional activation and expression of MMP-10, in response to VEGF 
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Vorinostat, an HDACi for T-cell lymphoma, was evaluated in cancers overexpressing 
HDAC7 with the intention of addressing the effect of inhibiting HDAC7 activity (Dok-
manovic et al., 2007). Vorinostat treatment resulted in a reduction of HDAC7 mRNA 
level with no change in protein stability (Dokmanovic et al., 2007). Cutaneous T cell 
lymphoma causes lesions to appear on the skin and although there is no cure, Vori-
nostat has shown a benefit for a third of patients by either reducing the amount of 
skin affected or relieving the symptoms of pruritus (Duvic & Vu, 2007). 
 In comparison, HDAC7 suppression by small interfering RNA-mediated knockdown 
was associated with growth arrest but without detectable changes in acetylation of 
histones or p21 gene expression, the key biomarkers of ‘conventional’ histone 
deacetylase activity (Dokmanovic et al., 2007). Therefore, despite being overex-
pressed in cancers, this strongly supports the suggestion that HDAC7 exerts its activ-
ity not via ‘conventional’ HDAC nuclear activity and histone acetylation but rather by 
modulation some other cellular functions, which may or may not be dependent on 
its acetylation activity. Subsequently, in light of the weak enzymatic activity and cel-
lular location, the repression of HDAC7 protein expression by Vorinostat also strongly 
suggests a regulatory involvement of HDAC activity upon expression of HDAC7 itself, 
implying intra-family regulation pathways. 
 
I.5 Rationale and Aims 
The objective of much current oncology research is the identification of therapeutic 
targets and the development of novel effective therapeutic agents. This is especially 
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true for those cancers which are increasing in incidence and for which current ther-
apies are not truly effective, such as NSCLC where conventional chemotherapy has 
minimal efficacy. A major drawback of many current anticancer agents is their lack 
of tumour specificity, which has prompted a renewed focus on targeted therapy 
based on pathways altered during the pathogenesis of lung cancer. 
This study aimed to characterise the relationship between matrix metalloproteinase-
10 (MMP-10) and the histone deacetylase (HDAC) class of enzymes, particularly 
HDAC7. In particular, the mechanism by which HDAC7 influences expression of MMP-
10 and whether this involves enzymatic activity of HDAC7, or a functionality of this 
enzyme independent of its deacetylase activity. 
The first aim of this study was to demonstrate whether a relationship existed be-
tween HDAC7 and MMP-10. Studies have suggested an inverse correlation between 
HDAC7 and MMP-10 expression in clinical NSCLC; therefore, this was to be explored 
in an in vitro model of NSCLC. 
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Chapter II - General Materials and Methods 
II.1 Chemicals 
All general reagents were obtained from Sigma-Aldrich Company Ltd (UK) including 
Roswell Park Memorial Institute (RPMI) medium, OptiMEM Reduced Serum medium, 
Foetal Bovine Serum (FBS), L-Glutamine, Trypsin/EDTA, Hanks’ Balanced Salt Solution 
(HBSS), Ethanol (EtOH), Phosphate buffered saline (PBS), Agarose, Ethidium Bromide, 
β-mercaptoethanol (β-ME), Ethylenediaminetetraacetic acid (EDTA). 
 
II.2.1 Growth and maintenance of Non-Small Cell Lung Carcinoma (NSCLC) cell line 
Human NCl-H460 (H460) cells were obtained from the America Type Culture Collec-
tion (ATCC); HTB-177. These cells are an immortalised non-small cell lung carcinoma 
cell line derived from the pleural effusion of patient with a large cell carcinoma of the 
lung. 
H460 cells were grown in vitro and routinely maintained as monolayer cultures in 
RPMI medium that was supplemented with 10% FBS and 2mM L-Glutamine, (termed 
‘complete media’). In 75cm2 tissue culture flasks (Corning, UK) and incubated at 37°C 
in a humidified atmosphere of 5% CO2 and 95% air. 
H460 cells were routinely passaged when they reached 75-85% confluency (in expo-
nential growth phase). The media was discarded and the cells washed twice with 
HBSS to remove any excess media. Cells were harvested by trypsinisation using pre-
warmed 0.25% Trypsin-EDTA (Sigma, UK), centrifuged (Heraeus Megafuge 16, Ther-
mofisher Scientific, UK) at 1000rpm (200 x g) for 5 minutes at room temperature and 
the resultant cell pellet resuspended in fresh complete media to neutralize activity 
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of trypsin, cells were then either split into new flasks or stored as a pellet at -20°C, if 
required for future analysis.  
 
II.2.2 Manual counting of cell number 
Cells detached using 0.25% trypsin-EDTA solution and re-suspended in fresh com-
plete medium were counted as follows. A 10μl sample of the cell suspension was 
placed into a hemocytometer chamber and counts were obtained from 5 grids of the 
hemocytometer chamber. Cell counts were calculated as the mean of the 5 counts; 
cell numbers expressed as (mean cell count) x 104/ml medium. The value was ad-
justed in light of the total suspension volume to obtain total cell number per flask. 
 
II.2.3 Cryopreservation of cells 
Confluent cells were harvested and re-suspended in fresh complete media. Approxi-
mately 1x108 cells in a final volume of 1ml were transferred to a 2.0ml NuncTM Cry-
oTube TM (Fisher Scientific) to which 100µl Dimethyl sulfoxide (DMSO) was added 
(final concentration of 10%) to protect the cells against the freezing process. Tubes 
were placed into a cryogenic freezing container (Mr. Frosty, Thermofisher Scientific, 
UK) submerged in isopropanol, and the container transferred into a -80°C freezer 
overnight. Cell vials were then transferred to liquid nitrogen for long term storage; 
the use of the cryogenic ‘Mr. Frosty’ freezing container permits a rate of cooling of -
1°C/minute, the optimal rate for cell preservation. 
76 | P a g e  
 
II.2.4 Monitoring of cell proliferation and viability using xCELLigence real-time cell 
analyzer system (xCELLigence RTCA) 
The xCELLigence system allows monitoring of cell proliferation and viability in real 
time using impedance of an electric current to non-invasively quantify cell adherence 
(depicted in figure II.1). Cells are seeded into E-plates (incorporating interdigital elec-
trodes into bottom of wells), the interaction of cells with the electronic biosensors 
generates a cell-electrode impedance response that signifies the surface area of the 
respective well impeding a low current, indicating cell viability and morphology, and 
consequently cell number (see figure II.1). 
Cells were seeded into wells of the E-plate at the required cell density (range 250-
8000 cells/well). THE RTCA DP software was set up according to the manufacturer’s 
instructions, including experimental layout (cell name, cell number, designation of 
well use) and experimental schedule (number of readings, interval of readings). Prior 
to cell addition to E-plates, 100µl of cell media was added to each well and a back-
ground reading carried out. After the background reading was performed, 100µl of 
cell suspension (at 2x required concentration) was added to each well in duplicate, 
with 100µl of media added to the control lane. The E-plate was left at room temper-
ature for 30 minutes, to allow cell distribution and initial attachment. The E-plate was 
then transferred to the cradle of the RTCA DP analyser, within the incubator, and the 
experiment initiated. During the experiment, the data was viewed in real-time to 
monitor changes in cellular impedance, indicative of cell attachment, morphology 
change, and cell growth. Data is displayed as cell index, an arbitrary value based on 
changes in cellular impedance relative to cell-free background. 




Figure II.1 Principle of impedance based cell detection. In the absence of cells, electric 
current flows freely through culture medium, completing the circuit between the 
electrodes.  As cells adhere to and proliferate on the surface of the well, electrodes 
current flow is impeded, providing an extremely sensitive readout of cell number, 
cell size/morphology, and cell-substrate attachment quality [adapted from ACEA Bi-
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II.2.5 Determination of cell viability using the MTT assay 
The MTT assay is a cell viability analysis using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide; thiazolyl blue) compound. This technique involves 
conversion of MTT from its soluble form (yellow in colour), to its insoluble form (pur-
ple colour). This transformation between soluble to insoluble form only occurs in liv-
ing cells via the active mitochondrial hydrogenases. After treatment with a drug, its 
potential cytotoxic effect can be determined by the number of living or dead cells 
and this is quantified by the colour change (method adapted from; Mosmann, 1983).  
Cells were seeded on 96-well plates, and incubated for the designated time frame, 
the media removed and replaced with fresh media containing 1mg/ml MTT (method 
adapted from; Mosmann, 1983). Plates were incubated at 37°C for 4 hours, allowing 
mitochondrial dehydrogenase in viable cells to metabolise MTT and produce purple 
crystals of formazan. Media was carefully removed (so as not to disturb formazan 
crystals) and 150μl of DMSO added to each well to solubilise the formazan and pro-
duce a uniform colour in each well. The plate was analysed using a plate reader (Mul-
tiskan Go, Thermo Scientific) measuring absorbance at 540nm, where the absorb-
ance reading, is directly proportional to cell number (Morgan, 1998). 
 
II.3 Analysis of gene expression by reverse transcription polymerase chain reac-
tion (RT-PCR) 
RT-PCR is a technique used to detect the RNA expression levels in a sample. It works 
by converting RNA to cDNA using the reverse transcriptase enzyme and this cDNA is 
used as a template for amplification in PCR.  
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II.3.1 RNA Extraction 
Cells were grown as described in section II.2.1. Excess media was removed from cell 
pellets and RNA extracted using an RNeasy Mini Kit (Qiagen, UK). Briefly, the cell pel-
let was disturbed by the addition of lysis buffer; buffer RLT and the cell solution vor-
texed until the pellet was completely dispersed. The cell solution was added to a QI-
Ashredder spin column and centrifuged for 2 minutes at 17,000 x g, at room temper-
ature to homogenise the lysate. Solution transferred to spin column with equal vol-
ume of 70% EtOH and centrifuged at room temperature for 15 seconds at 10,000 x 
g, discarding the flow through. Buffer RW1 (700μl) was added to the RNeasy spin 
column and centrifuged at room temperature for 15 seconds at 10,000 x g, discarding 
the flow-through. Next, buffer RPE (500μl) was added to the spin column and the 
solution centrifuged at room temperature for 15 seconds at 10,000 x g. This step was 
repeated but centrifugation extended to 2 minutes, to dry the column and prevent 
ethanol carryover to RNA elution. Finally, RNase-free water (30μl) was directly added 
to the spin column membrane and the column centrifuged at room temperature for 
1 minute at 10,000 x g to elute RNA. 
Samples were analysed by measuring the relative absorbance spectrophotometri-
cally (MultiSkan GO, Thermo Scientific, Finland) at 260nm and 280nm using a quartz 
cuvette. RNA purity is indicated by a 260:280 ratio of absorbance between 1.7-2.0. 
The concentration of RNA samples was analysed by assuming absorbance of 1.0 at 
260nm is equivalent to 40μg/ml RNA (Warburg & Christian, 1942). Prior to measure-
ment of absorbance, RNA samples were diluted into water. 
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II.3.2 cDNA synthesis: Reverse transcription 
dT23VN primer (2μl) (New England Biolabs, UK) was added to 1µg of total RNA and 
the volume adjusted to 8μl using RNase-free water in a 0.2ml microcentrifuge tube. 
RNA samples were incubated at 70°C for 5 minutes, after which they were promptly 
put on ice to ensure primer annealing. To each RNA sample a cDNA synthesis mix was 
added consisting of: 10μl of 10x M-MuLV reaction mix and 2μl of 2x M-MuLV enzyme 
mix. This was mixed and incubated at 42°C for 1 hour, after which time the enzyme 
was inactivated by heating each sample to 80°C for 5 minutes. Samples were diluted 
with RNase-free water and vortexed to ensure proper mixing. cDNA samples were 
stored at -80°C. Appropriate negative controls (-RT) were constructed; RNA samples 
were treated as described but without the addition of M-MuLV enzyme mix in the 
cDNA synthesis mix, to demonstrate the level of genomic DNA contamination in sub-
sequent PCR analyses.   
 
II.3.3 PCR primer design 
GAPDH primer design was based on findings of Daja et al. (2003) (Daja et al., 2003). 
MMP-10, HDAC7 and HDAC3 were designed in house (Table II.1). A BLAST search 
(http://www.ncbi.nlm.nih.gov/blast/index.shtml) was carried out to check homology 
and specificity of primers and revealed that all primers were specific to the relevant 
human DNA sequence. All Primers were obtained from Invitrogen Life Technologies 
(Glasgow, UK). Primers were made up to 10μM stock solutions in sterilised water, 
and stored at -20°C. 
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Table II.1: Sequences of primers used for RT-PCR to amplify to following human 
genes; HDAC7, HDAC3, MMP-10 and the housekeeping gene GAPDH. Supplied by 








Forward 5’-AGTTTGGCTCATGCCTACCC-3’ 521 
Reverse 5’-AAAACGGTGTCCCTGCTGTT-3’ 
GAPDH Forward 5’-CCACCCATGGCAAATTCCATGGCA-3’ 598 
Reverse 5’-TCTAGACGGCAGGTCAGGTCCACC-3’ 
HDAC7 Forward 5’-CGCTCCCTGGGATAACTGTC-3’ 538 
Reverse 5’-CTGATGAACCTGGCAGGAGG-3’ 




Table II.2 RT-PCR conditions used for MMP-10, HDAC7, HDAC3 and the housekeeping 
gene GAPDH. 
 




Number of cycles 
MMP-10 65 60 35 
GAPDH 60 90 25 
HDAC7 55 60 25 
HDAC3 60 90 25 
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II.3.4 PCR amplification of cDNA 
PCR reactions were performed using the Taq PCR kit (New England Biolabs, UK). All 
reaction components were kept on ice throughout. Each cDNA sample (5μl) was 
placed in a 0.5μl thin-walled PCR microcentrifuge tube to which was added the fol-
lowing reaction mix: 10μl of Taq 2x Master Mix, 0.2μl forward primer (10μM), 0.2μl 
reverse primer (10μM) and 4.6μl RNase-free water (total reaction volume; 20μl). The 
contents of each tube were mixed well and briefly centrifuged. All samples under-
went the following PCR programme, 94°C for 4 minutes followed by cycles of 94°C 
for 30 seconds, primer annealing for 30 seconds (Table II.2) and elongation at 72°C 
(Table II.2). Each program finished with 10-minute incubation at 72°C to ensure com-
plete elongation of newly synthesised cDNA. 
After cycling was complete, all PCR samples were stored at 4°C ready for analysis. 
The following controls underwent the PCR protocol described above; Positive con-
trols consisted of sample DNA amplified in the presence of GAPDH primers whilst 
purity controls omitted cDNA. Negative (RT-) controls consisted of RT-PCR products 
created without the addition of M-MuLV enzyme mix (as detailed in section II.3.3).  
 
II.3.5 Agarose gel electrophoresis to analyse PCR products 
RT-PCR products were separated through a 1% v/w agarose/Tris base, acetic acid 
EDTA (TAE) gel containing 0.01% ethidium bromide. Prior to loading the gel, 10% 
loading dye (30% glycerol, 0.25% bromophenol blue) was added to each PCR reaction 
to allow sample visualisation. 1kb Plus DNA Ladder (2μl) (Invitrogen Life Technolo-
gies, UK) was loaded onto the gel, allowing for later verification of PCR product size. 
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Electrophoresis was carried out in 1 x TAE buffer (40mM Tris, 20mM acetic acid, and 
1mM EDTA) at 100V for 1 hour to separate PCR products. cDNA was visualized in the 
gel under a UV light using the ChemiDoc MP imaging system with the image lab anal-
ysis software. 
Densitometry was carried out using image J to quantify RT-PCR expression data, ex-
pressed as fold change compared to control. 
 
II.4 Analysis of protein expression by western blotting 
Western blot (also known as immunoblotting) is an important analytical technique 
that is used to identify a specific protein of interest from a cell sample, by separating 
proteins according to their molecular weight via gel electrophoresis and transferring 
these proteins to a PVDF membrane to probe for the protein of interest, using a spe-
cific antibody. 
 
II.4.1 Preparation of cells for western blotting 
Cells were grown to subconfluency in 6 well plates. Ice cold lysis buffer was applied 
directly onto the cell monolayer and a cell scraper (Sarstedt, Germany) used to collect 
the extract. The sample was centrifuged at 17,000 x g for 10 minutes at 4°C, the su-
pernatant collected and the pellet discarded.  
II.4.2 Protein concentration determination for western blotting 
A Bradford assay is an analytical technique that is used to measure the amount of 
protein in a sample. Initially, 2µl of sample was removed and mixed with 38µl of di-
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ionised water, vortexed. For each sample, 10µl was removed and added to the wells 
of a 96 well plate, several known concentration samples (standards) were created 
using BSA (range 0-1 µg/µl), 200µl of Bradford assay reagent (Bio-Rad, UK) was added 
to each of the wells containing the protein sample, and this was incubated for 5 
minutes at room temperature. After 5 minutes, the plate was put into a microplate 
spectrophotometer (MultiSkan GO, Thermo Scientific, Finland) and read at a wave-
length of 550nm. A calibration graph was constructed by plotting the absorbance of 
the standards against their concentrations, with this used to determine the test sam-
ples concentrations by interpolating.  
 
II.4.3 Polyacrylamide gel electrophoresis 
Proteins were separated through 10% polyacrylamide SDS gels (for composition of 
gel see appendix A). Each lane was loaded with a relevant amount of sample (30μg 
following optimisation) diluted in extraction buffer and sample buffer (Laemmli 2x 
concentrate) to make a final volume of 30μl. Samples were denatured at 95°C for 3 
minutes and immediately transferred to ice prior to loading. Gels were loaded into 
running apparatus (Bio-Rad, UK) immersed in electrophoresis running buffer (25mM 
tris, 200mM glycine, 3.5mM SDS) and the samples loaded into the gel. In addition, 
one lane was loaded with Precision plus protein ladder (Bio-Rad) to allow for latter 
protein mass determination. Electrophoresis was performed at 200V for 45 minutes 
until the marker of the relevant to the size of the protein of interest was located in 
the centre of the gel.  
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II.4.4 Protein transfer to PVDF membrane 
Protein was transferred from the acrylamide gel to a PVDF membrane (Ambersham 
Hybond P0.45, GE Healthcare Life Sciences), the gel and membrane were assembled 
into a sandwich (set-up shown in figure II.2), and placed in a transfer kit (VWR), im-
mersed in transfer buffer (20mM Tris, 150mM glycine, 20% methanol). The transfer 
tank was placed in an ice bath and the transfer performed for 60 minutes at 300mA. 
After protein transfer the membrane was removed, rinsed in H2O and then immersed 
in 5% w/v non-fat dry milk solution in TBS-Tween (10mM Tris, 150mM NaCl (pH8.5), 










Figure II.2 Illustration of western blot transfer set-up. PVDF membrane placed closest 
to the cathode to allow negatively charged proteins on the acrylamide gel to be trans-

















+     +     +     +     +     + 
-    -    -    -     -    -    -    - 
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II.4.5 Antibody incubation 
Antibodies were diluted to their final concentration (Table II.3) in 1% w/v non-fat dry 
milk solution in 0.1% TBS-Tween the membrane submerged in it, and this incubated 
overnight at 4°C with agitation. The membrane removed then excess antibody 
cleared by washing the blot 3 times for 5 minutes in 0.1% TBS-Tween. The blot was 
incubated with the appropriate horseradish peroxidase conjugated secondary anti-
body at a 1:2000 dilution in 1% w/v non-fat dry milk solution in TBS-Tween, for 60 
minutes at room temperature. Blots were rinsed for a further 3 times for 5 minutes 
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Table II.3 Western blotting conditions for MMP-10, HDAC7, HDAC3 and the house-
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II.4.6 Visualisation of antibody binding 
Antibody binding was detected chemi-luminescently using ECL (Bio-Rad). Western 
blots were exposed to ECL for 3 minutes at room temperature; excess reagent blot-
ted from the membrane, the membrane sealed in a saran wrap, and chemi-lumines-
cence detected using the ChemiDoc MP imaging system and associated image lab 
analysis software (4.1), to detect proteins of interest.  
Densitometry was carried out using image J to quantify protein expression data, ex-
pressed as fold change as compared to control. 
 
II.5 Statistical analyses 
All statistical analyses on MMP-10, HDAC7 and HDAC3 gene and protein expression 
data were performed using GraphPad Prism (version 7). Unpaired t-tests were used 
to analyse experiments with only one experimental treatment group versus vehicle; 
whereas a one-way ANOVA (analysis of variance) was used when multiple treatment 
groups were compared to vehicle. The ANOVA indicated equal or non-equal variance; 
where variance was found to be non-equal a Dunnetts test was used. For all tests, a 
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Chapter III: Expression of HDAC7 and MMP-10 in human NSCLC cell line in vitro 
III.1 Introduction 
Lung cancer is the leading cause of cancer deaths in both men and women, with more 
than 1 million deaths worldwide each year (Torre et al., 2015; Petty et al., 2004; 
Wang et al., 2016). Unfortunately, due to late prognosis and poor treatment re-
sponse, this therapeutic area has shown the highest failure rate in clinical trials over 
the last 30 years (Constant et al., 2015).  Consequently, greater understanding of 
NSCLC pathophysiology and molecular alterations therein are paramount to improv-
ing treatment of this life-threatening disease (Petty et al., 2004). 
Next-generation sequencing has revealed that more than 50% of human cancers har-
bour mutations in enzymes that are involved in chromatin organization (Jones et al., 
2016). Tumour cells are now known to employ epigenetic alterations to drive tumor-
igenesis and the hallmarks of cancer, and from a therapeutic perspective to support 
their escape from chemotherapy and host immune surveillance (Wilting & Dannen-
berg, 2012). Hence, a growing emphasis of recent drug discovery efforts has been on 
targeting the epigenome, including DNA methylation and histone modifications 
(Jones et al., 2016). Histone modifications are post-translational modifications 
(PTMs) to histone proteins which can impact gene expression by altering chromatin 
structure or recruiting histone modifiers (Bannister & Kouzarides, 2011), including 
methylation, phosphorylation, acetylation, ubiquitination and sumoylation (Duan & 
Walther, 2015). The most common of these; histone acetylation, is the enzymatic 
addition of an acetyl group (COCH3) from acetyl coenzyme A to the histone tails 
(Sterner & Berger, 2000). The process of histone acetylation is tightly involved in the 
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regulation of many cellular processes including chromatin dynamics and transcrip-
tion, gene silencing, cell cycle progression, nuclear import (Cohen et al., 2011). The 
modifying enzymes involved in histone acetylation are called the histone acetyltrans-
ferases (HATs) (Cohen et al., 2011), in opposition to the HATs are the histone 
deacetylases (HDACs), which catalyse the hydrolytic removal of the acetyl group on 
the lysine tails of the histones, causing chromatin condensation and ultimately tran-
scription repression (Legube & Trouche, 2003). Aberrant regulation of gene expres-
sion is at the basis of many human diseases and notably of many forms of cancer, 
including NSCLC (Gallinari et al., 2007; Zochbauer-Muller et al., 2002). Osada and col-
leagues found reduced expression levels of class II HDACs in clinical NSCLC, is linked 
to poor prognosis in patients (Osada et al., 2004). 
Within the HDAC family the class IIa HDAC; HDAC7 has received little attention. How-
ever, a role for this HDAC has been shown in vascular development (Chang et al., 
2006; Ha et al., 2008). In contrast to class I, these class II HDACs exhibit low deacety-
lase activity towards histones, and preferentially target non-histone proteins (de 
Ruijter et al., 2003). HDAC7 has been linked to the regulation of the secreted endo-
proteinase; MMP-10 (Chang et al., 2006). MMP-10 over expression has been demon-
strated in NSCLC (Gill et al., 2004), with it thought to play a role in the early stages of 
tumour development, being key in the remodelling of vascular endothelial cells dur-
ing angiogenesis, with increased expression linked to decreased tumour growth in 
vivo (personal communication by Gill, figure I.3). Therefore, there is a rationale for 
viewing MMP-10 and potentially HDAC7 as of molecular importance and therapeutic 
target in NSCLC (discussed in chapter I). The aim of this chapter is to characterise the 
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expression and activity of HDAC7 and MMP-10 in a human cell line (H460) to estab-
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III.2 Methods 
III.2.1 H460 cell line growth kinetics, by manual counting 
Growth kinetics of H460 cells were characterised in order to utilise exponential cell 
growth. Cells were trypsinised and counted as described in section II.2.2, with 1x104 
cells plated into each of the ten 25cm2 flasks in a total volume of 10mls per flask. 
H460 cell flasks were maintained at 37°C in conditions of 5% CO2 (as described in 
section II.2.1) and cell counts performed every 24 hours, for a total of 10 days. 
Growth curves were repeated 3 times using different passages for the cells, with 
growth curves plotted as a mean of 3 growth curves.   
 
III.2.2 H460 cell line growth analysis, by MTT metabolism 
Growth curve analysis for H460 cells were conducted in 96-well plates. Varying cell 
densities of each cell line were seeded (25, 50, 100, 250, 500, 1000 and 2000 cells 
per well) and monitored for 5 days to show cell growth kinetics. On each day, the 
increase in cell number for each cell seeding density, was calculated using the MTT 
assay (method described in section II.2.5).  
 
III.2.3 H460 cell line growth analysis, by xCELLigence RTCA 
Growth curve analysis was conducted in real-time using the xCELLigence RTCA, using 
the method described in section II.2.4. Using a cell concentration of 80,000 cells/ml, 
serial dilutions were created to provide a range of cell concentrations ranging from 
80,000 to 2500 cells/ml. The software was programmed as described in section II.2.4, 
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background readings performed, and 100µl cell suspension added to relevant wells 
(corresponding to 8000-250 cells/well). Cellular analysis was performed over a 5-day 
period, with readings taken every 30 minutes during this time (250 sweeps x 30 
minutes). Cellular growth was determined by analysis of cell index over time. 
 
III.2.4 Expression of HDAC7 and MMP-10 in human H460 NSCLC cell line in vitro 
H460 cells were plated at a density of 4x105 cells per well in 6 well plates and incu-
bated in complete media for 24 hours. Following incubation, mRNA was extracted, 
converted to cDNA (as described in section II.3.2), and used as a template for reverse 
transcriptase with primers specific to HDAC7 and MMP-10 (see table II.1 for primer 
sequences and table II.2 for optimisation data). RT-PCR products were separated us-
ing agarose gel electrophoresis, visualised and analysed as described in section II.3.5. 
 
III.2.5 Expression of HDAC7 and MMP-10 proteins in human H460 NSCLC cell line 
in vitro 
H460 cells were plated at a density of 4x105 cells per well in 6 well plates and incu-
bated in complete media for 24 hours. Following incubation, protein was extracted 
and quantified (as described in section II.5.2), samples prepared and proteins frac-
tionated using SDS-PAGE (see section II.5.3 for details). Proteins were transferred to 
a membrane and probed with antibodies to detect human MMP-10 and HDAC7, as 
described in section II.5.4/II.5.5 (see table II.3 for antibody details and concentra-
tions).   
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III.2.6 Evaluation of MMP-10 protein activity levels in human H460 NSCLC cell line 
in vitro 
H460 cells were plated at a density of 4x105 cells per well in 6 well plates and incu-
bated in complete media for 24 hours. To assess the levels of active endoprotease 
enzymes present in cell media, aliquots of media were removed at various time 
points over the duration of the time course (24-96h). The fluorometric enzyme assay 
was performed in a 96 well plate by incubating 10μl of media with 50μg of fluoro-
genic substrate M-2110 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂) in 
80μl of MMP activity buffer (100 mM Tris-HCl pH 7.6, 10 mM CaCl2, 100 mM NaCl, 
0.16% v/v Brij-35); total reaction volume of 100μl. Fluorescence was measured (ex-
citation = 325 nm; emission = 393 nm) over a 600-minute incubation period at 37°C. 
For each sample, the relative activity of the initial linear enzyme activity was calcu-
lated, and activity expressed as change in fluorescence per hour per 4x105 cells. The 
reproducibility and reliability of the assay were determined using samples obtained 
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III.3 Results 
III.3.1 NSCLC cell line growth kinetics, by manual counting 
Growth patterns of H460 cells were determined using three methodologies to eval-
uate growth kinetics and characterisation of the value of each methodology. Growth 
curves are shown in figure III.1, from this data, the duration of the exponential phase 
and hence optimum time of harvesting for H460 cells was identified. The growth 
phases were identified as; lag phase 0-48 hours; exponential phase 48-120 hours; 
plateau phase >120 hours. Doubling time in exponential growth phase was 19.2 
hours. For drug analysis in a T25cm2 flask, the addition of 5-50x104 cells/flask would 
allow for drug addition during the exponential phase. 
 
III.3.2 xCELLigence growth curve analysis 
Classically determination of timings for drug addition or sample collection in in vitro 
assays is based on a time point that is convenient (24 h post seeding) rather than 
based on empirical or behavioural data from the cells (Kho et al., 2015). However, 
the real-time data provided by the xCELLigence RTCA reveals extra information re-
lated to the behaviour, growth and health of the cells, which can be used to guide 
and improve the experimental design. This information can be used to identify an 
appropriate time window for drug treatments and to ensure that this occurs consist-
ently across studies or experiments. H460 cells were seeded at a high density (8000, 
4000 and 2000 cells/well) and low density (1000, 500 and 250 cells/well) to deter-
mine an ideal seeding density for subsequent experiments. Low density seeding cell 
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numbers were found to have a long lag time and took between 61-101 hours to reach 
exponential phase of growth, discounting these densities for subsequent studies. The 
highest cell number seeded (8000 cells/well) did not exhibit lag phase of growth, dis-
counting this cell number from subsequent studies because drug addition would 
have to be almost instant after seeding cells, not allowing for an incubation period. 
4000 cells/well was subsequently chosen as the ideal cell number for subsequent 
drug treatment studies, because this would allow a 24-hour incubation period prior 
to drug addition (as carried out in other cellular growth studies) and the cells to be 
in exponential growth phase during drug incubation. The growth phases for 4000 
cells/well were identified as; lag phase 0-32 hours; exponential phase 32-72 hours; 
plateau phase; >73 hours. Doubling time in exponential phase was 18 hours. Table 
III.3 compares doubling times and different phases of growth with different densities 
of H460 cells. 
 
III.3.3 MTT growth curve analysis 
In order to observe the growth characteristics of the H460 cell line, in which the cy-
totoxicity of compounds was to be assessed, growth curves of different cell densities 
were performed and analysed by the MTT assay (figure III.3). The three highest den-
sities (2000, 1000 and 500 cells/well) were discounted for subsequent toxicity studies 
because the cell growth plateaued (2000 and 1000 cells/well) or slowed (500 
cells/well) during the assay (>72 hours). The lowest cell density (100 cells/well) was 
also discounted for subsequent studies because it doesn’t reach exponential phase 
of growth until 48 hours, meaning the subsequent toxicity experiments would be 
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carried later than other assays. Therefore, 250 cells per well was chosen as the seed-
ing density during cytotoxicity assays because the cells are in the exponential phase 
of their growth cycle for the duration of the assay, which allowed drug addition of 
subsequent experiments after 24 hours of cell growth(figure III.3).    
  
 
III.3.4 Optimisation of RT-PCR evaluation of MMP-10 and HDAC7 
To assess the gene expression of the matrix metalloproteinase; MMP-10 and the 
class IIa HDAC; HDAC7 in NSCLC in vitro, primer pairs were optimised in order to iden-
tify an appropriate annealing temperature, elongation time and number of PCR cy-
cles to yield optimum reaction products (table II.2 for optimised primer conditions). 
The amount of cDNA used in each PCR reaction was optimised using a range of cDNA 
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Figure III.1 Growth of H460 cells in vitro, determined by manual counting method. 
1x104 cells were plated into 10x25cm2 flasks, every 24 hours over the course of 10 
days, cells were counted (as described in section II.2.2). Data representative of the 























































Figure III.2 Characterisation of H460 growth kinetics using the xCELLigence RTCA sys-
tem. Cells were seeded at a range of titrations to identify the ideal seeding density 
and reveal time windows for drug treatment.  Cells grown at A) Low density; 1000, 
500, 250 cells/well and B) High density; 8000, 4000 and 2000 cells/well. Curves rep-
resent the mean Cell Index value from >2 wells ± SD. 
 
Table III.1 Comparison of growth phases and doubling times in different seeding 
densities of H460 cells 
 
Seeding density 










250 0-101 101->119 >119 17.0 
500 0-85 85->119 >119 18.7 
1000 0-61 61-93 >93 17.9 
2000 0-51 51-95 >95 18.7 
4000 0-32 32-73 >73 18.7 
8000 0 0-37 >37 17.2 




Figure III.3 Growth curve analysis of H460 cells, using the MTT assay. Different cell 
densities (25-2000 cells per well) were grown over a 96-hour incubation period to 
identify a suitable cell number to use in subsequent toxicity studies. Curves represent 
the mean Cell Index value from >4 wells ± SD. 
 
Table III.2 Average doubling times during exponential growth phase of H460 cells, 
determined using three methodologies 
 
Growth curve analysis method Average doubling time (hours) 
Manual  19.2 ± 1.8 hours 
xCELLigence 18 ± 1 hour 
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Figure III.4 Identification of optimal cDNA concentration for RT-PCR analysis. mRNA 
was extracted from H460 cell lysates and RT-PCR analysis was performed on different 
concentrations of cDNA. Optimum cDNA concentration identified as 50ng NSCLC 
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III.3.5 Time-dependent expression of MMP-10 and HDAC7 in NSCLC in vitro 
In order to use a suitable in vitro model of NSCLC, H460 cell lines had to be charac-
terised for the gene expression of HDAC7 and MMP-10, this was carried out via RT-
PCR. Bands of relevant sizes were present in the cells, indicative of a positive result 
for HDAC7 and MMP-10 expression in H460 cells (figure III.5). MMP-10 gene expres-
sion revealed stronger expression over time, showing a time-dependent increase. 
There was no difference in HDAC7 gene expression over time. 
 
III.3.6 Expression of HDAC7 and MMP-10 protein in H460 NSCLC cell line in vitro  
Western blot analysis confirmed H460 cells express both MMP-10 and HDAC7 pro-
tein, with bands of relevant sizes (figure III.6). MMP-10 can exist as both an inactive 
proenzyme and active enzyme, however such analyses could not be achieved due to 
the inability of this antibody to achieve a positive result for both the active and inac-



























Figure III.5 RT-PCR analysis of MMP-10 and HDAC7. H460 cells were grown for 12-72 
hours, mRNA was extracted from cell lysates and gene expression was evaluated by 
RT-PCR. Product sizes; GAPDH, 598 bp; MMP-10, 521 bp; HDAC7, 538bp. MMP-10 














































Figure III.6 Western blot analysis of MMP-10 and HDAC7 protein. H460 cells were 
grown for 24 hours, protein was extracted from the cell lysates and protein expres-
sion was evaluated by SDS PAGE. Both pro-MMP-10 (57kD) and HDAC7 (105kD) ex-
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III.3.7 Levels of active MMP-10 in H460 cell line in vitro 
III.3.7.1 Demonstration of MMP selectivity of M-2110 protein substrate 
A continuous fluorometric assay using substrate M-2110 with different MMP recom-
binant proteins (-10, -9, -3 and -2) was carried out to assess the selectivity of the 
substrate. The substrate showed highest selectivity against active MMP-10 and 
MMP-3 protein, with low activation by MMP-9 and negligible activation by MMP-2 
(figure III.7). This substrate could therefore be used for subsequent assay evaluations 
for active MMP-10 in NSCLC. 
 
III.3.8 Secretion of enzymatically active MMP-10 by H460 NSCLC cell line in vitro 
Levels of active MMP-10 were assessed in NSCLC in vitro, using a continuous fluoro-
metric assay over a 24-96-hour time course, using the MMP-10 specific substrate; M-
2110 (figure III.8) and normalized to cell number. Active MMP-10 was detected in 
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Figure III.7 Continuous fluorometric assays of MMPs with M-2110 substrate (Mca-
Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂). Assay was performed at 37°C 
by reacting 1μM substrate with 200ng of MMPs in 100μl solution of assay buffer. 





































































Figure III.8 Increased secretion of active MMP-10 in vitro NSCLC, over time continu-
ous fluorometric assay demonstrated a time dependant increase in active MMP-10. 
Assay was performed at 37°C by reacting 1μM substrate with 10µl media in 100μl 
solution of assay buffer. Fluorescence was read with λex=325nm and λem=393nm. Val-
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III.3.9 Comparison of time-dependent expression of MMP-10 in H460 NSCLC cell 
line in vitro 
Table III.3 Comparison of time-dependent expression of MMP-10 gene, protein and 
















 12h 24h 48h 72h 96h 













n.d 0.05 0.09 0.12 0.15 
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III.4 Discussion 
This chapter serves to demonstrate the development of reproducible techniques for 
the detection and semi-quantification of MMP-10 expression levels in NSCLC in vitro. 
H460 cells which are of the large cell carcinoma sub-type were used as a model for 
in vitro NSCLC (Batra et al., 1998). H460 cells are immortalised and originally derived 
from a primary tumour of the lung removed via pleural effusion (Levina et al., 2008). 
Using a cell line over primary cells for in vitro studies is somewhat advantageous be-
cause the cells evade cellular senescence, can be grown for long periods of time, al-
lowing studies of molecular mechanisms to be investigated. H460 cells have been 
shown to be a useful NSCLC model system, as they exhibit a NSCLC phenotype and 
demonstrate clinically relevant responses to therapeutic agents (Kellar et al., 2015). 
In this study, three techniques were utilised to characterise cell growth kinetics.  
The role and significance of MMP-10 in cancer, especially NSCLC, has not yet been 
elucidated. However, several studies have demonstrated links between MMP-10 and 
tumour pathophysiology (Chang et al., 2006). For instance, high expression of MMP-
10 in lymphoma is associated with promotion of tumour growth (Van Themsche et 
al., 2017). In contrast, elevated expression of MMP-10 did not correlate with either 
clinical tumour stage or grade in several cancers, including bladder, colon, and NSCLC 
(Seargent et al., 2005; Gill et al., 2004). However, despite lacking correlation to path-
ogenic classification, this MMP is linked to an invasive phenotype in many preclinical 
cancer studies (Frederick et al., 2008; Zhang et al., 2014). Therefore, MMP-10 ap-
pears to have a major role in cancer, but with differing roles potentially associated 
with tumour origin, location or surrounding microenvironment such as degree of cell-
matrix interactions (Gialeli et al., 2011).  
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In NSCLC, MMP-10 expression and activity is elevated in both primary and metastatic 
disease (Justilien et al., 2012), but does not associate with tumour sub-type or path-
ogenesis (Gill et al., 2004). However, MMP-10 has been shown to play a key role in 
lung tumour formation via maintenance of the cancer stem-cell population and pro-
motion of metastatic genotypes in human NSCLC (Regala et al., 2011; Justilien et al., 
2012). Furthermore, the ability of MMP-10 positive NSCLC cells to form tumours in 
MMP-10-null mice implicates expression of MMP-10 in the tumour mass rather than 
the tumour microenvironment as being key to regulation of tumour growth (Justilien 
et al., 2012). However, the importance of tumour-expressed MMP-10 to tumour 
growth is reiterated by studies by Gill et al, (unpublished, Figure I.3) in which su-
praphysiological induced expression of MMP-10 in H460 NSCLC xenografts resulted 
in retardation of tumour growth in vivo. However, induced expression did not alter 
in vitro growth or survival (data not shown) consequently, despite being central to 
establishment and maintenance of the stem-cell phenotype, understanding the mo-
lecular mechanisms underlying regulation of MMP-10 has important implications for 
lung cancer pathogenesis and identification of therapeutic opportunities. In particu-
lar, how does elevated secretion of MMP-10 contribute to lung cancer development 
and how is MMP-10 expression and activity regulated? In this study, the H460 NSCLC 
cell line was shown to express MMP-10 at the genetic and protein level, with secre-
tion of proteolytically active MMP-10, in an in vitro culture system. Therefore, the 
H460 cell line is a viable model to characterise regulation and function of MMP-10 in 
NSCLC.  
Comparison of MMP-10 activity levels, as measured by a fluorometric assay and 
MMP-10 mRNA expression, demonstrated a correlation between the levels of active 
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MMP-10 and MMP-10 mRNA supporting MMP-10 gene expression as a marker for 
proteolytic activity. As expected, protein expression and MMP-10 proteolytic activity 
temporally followed gene expression. However, expression and activity of MMP-10 
increased over the duration of the study between 12 and 96 hours. The reason for 
this apparent increase in MMP-10 expression is unclear, but maybe a consequence 
of deplenishment of growth factors, increasing hypoxia, or alterations in cell-matrix 
interactions. Such relationships have been previously identified with MMP-10, albeit 
not in NSCLC (Garcia-Irigoyrn et al., 2014; Steele et al., 2011). 
A clear relationship has been shown between expression of HDAC7 and MMP-10, 
particularly in regulation of vascular integrity (Chang et al., 2006). MMP-10 expres-
sion has found to be overexpressed in several types of cancer as described in section 
I.3.5, with increased expression observed in NSCLC (Gill et al., 2004). HDAC7 has been 
linked to MMP-10 in vitro and in vivo; HDAC7 is thought to repress MMP-10 and has 
found to be under expressed in several types of cancers (examples include bladder 
cancer and NSCLC). Subsequently, in addition to MMP-10 facilitating maintenance of 
the cancer stem cell, a role for MMP-10 is postulated in the control of tumour angi-
ogenesis and ultimately metastatic potential (Chang et al., 2006). Timely regulation 
of MMP-10 is important to endothelial motility and vascular development with un-
regulated activity being detrimental to successful angiogenesis, providing an expla-
nation to retardation of NSCLC tumour growth in vivo. 
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Unexpected and specific role for HDAC7 in the maintenance of vascular integrity and 
have important implications for understanding the mechanisms of angiogenesis and 
vascular remodeling during cancer development (Chang et al., 2006). 
The potential that HDAC7 regulates MMP-10 expression and vascular integrity has 
potentially important implications in the treatment of NSCLC (Chang et al., 2006).  
Inhibition of HDAC7 in tumours and consequent upregulation of MMP-10 would have 
antiangiogenic consequences and eventually lead to regression of tumours due to 
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Chapter IV - HDAC7-mediated regulation of MMP-10 expression in NSCLC 
IV.1 Introduction 
The regulation of the secreted endopeptidase; MMP-10 has been linked to the class 
IIa HDAC; HDAC7, as discussed previously. Conventionally, HDACs are important in 
the regulation of gene transcription because they are responsible for the removal of 
the acetyl groups from histone tails, inducing chromatin condensation and a non-
permissive chromatin conformation, causing gene transcriptional repression 
(Barneda-Zahonero & Parra, 2012). This HDAC-regulated change in chromatin con-
densation prevents access of transcription factors to the promoter region of specific 
genes (Kouzarides, 2007). However, HDACs have now also been found to deacetylate 
non-histone proteins, with many of these non-histone targets being targets of class 
II HDACs (Peng & Seto, 2011). These non-histone protein targets include several tran-
scription factors (eg HIF1α), regulatory proteins (eg MLP), tumour suppressor pro-
teins (eg. P53), and cellular structural proteins, such as α-tubulin (Martin et al., 2007). 
The significance and diversity of these additional protein targets is only just beginning 
to be elucidated. However, there is strong evidence appearing to support type I 
HDACs, as being histone modifiers, and the type II HDACs as being largely protein 
deacetylases with cytoplasmic activities (Haberland et al., 2009), because class II 
HDACs exhibit low deacetylase activity against histones (de Ruijter et al., 2003). 
HDAC7, a class IIa HDAC member, plays an important role in angiogenesis and vascu-
lar integrity (Chang et al., 2006; Mottet et al., 2007). One mechanism involved in this 
process is the repression of the endoprotease; MMP-10 through regulation of the 
transcription factor; myocyte enhancer factor 2 (MEF-2). This transcription factor is 
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involved in control of MMP-10 expression, is a central regulator of differentiation of 
the endothelial cells (Ha et al., 2008; Chang et al., 2006; Murray et al., 2013) and is 
highly expressed within the developing endothelium (Chang et al., 2006). A clear re-
lationship between HDAC7 and MMP-10 is provided by mice knockout studies (Chang 
et al., 2006). In these HDAC7-modified mice, up-regulation of MMP-10 expression is 
observed in the perivascular region and a down-regulation of the MMP-10 antagonist 
TIMP1 is observed in the endothelial cells (Chang et al., 2006), offering a rationale to 
explain the loss of vascular permeability in these mice. Furthermore, Chang and col-
leagues also found that HDAC7 regulates vascular permeability through repressing 
MMP-10 expression and through inhibiting MEF2 activity (Chang et al., 2006). In prin-
ciple, the loss of HDAC7 triggers MMP-10 expression, leading to alterations in vascu-
lar homeostasis and blood vessel defects (Clocchiatti et al., 2011).  
In NSCLC, MMP-10 has previously been shown to be overexpressed, with high levels 
of proteolytically active MMP-10 detectable, and with MMP-10 localised in the tu-
mour mass rather than the stroma (Gill et al., 2004). Because elevated MMP-10 is 
central to regulation of vascular development; it induces remodelling of vascular ex-
tracellular matrix, capillary tube regression and vascular collapse, and because 
HDAC7 has been linked to the regulation of HDAC7 in vivo, with studies indicating an 
inverse correlation exists between HDAC7 and MMP-10, the relationship becomes a 
potential area of exploration in tumour progression mechanisms.  
IV. 1 .1 Aims and objectives 
The main objective in this chapter is to firstly evaluate the relationship between 
HDAC7 and MMP-10 expression. Studies have suggested an inverse correlation exists 
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between HDAC7 and MMP-10 in clinical NSCLC. Using H460 cells as a model of NSCLC 
in vitro; a comparison between the effects of silencing the expression of HDAC7 upon 
MMP-10 expression and activity, in addition to inhibiting its activity, upon the ex-
pression of MMP-10, was explored, this is to evaluate whether any relationship be-
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IV.2 Methods 
IV.2.1 Knockdown of HDAC7 expression in H460 NSCLC cells with siRNA 
Two sets of double stranded small-interference RNA (siRNA) for HDAC7 (sequence, 
Table IV.1) (Ambion, UK), were reconstituted to a stock concentration of 100μM in 
sterile dH2O. 
H460 cells were grown in 6 well plates (4x105 cells per well) (as described in section 
II.2.1), media was removed from the cells, the cells washed in HBSS, and 2ml/well of 
serum free media added to the cells. Lipofectamine 2000 (Invitrogen, UK), a trans-
fection agent, was reconstituted at a 1:35 ratio into OptiMEM (no serum or addi-
tives), to a final volume of 250μl. In a parallel tube, siRNA was diluted into 250μl 
serum free media; OptiMEM, at a range of working concentrations (1-100nM). The 
Lipofectamine (250μl) and siRNA (250μl) solutions were combined and the mixture 
incubated for 15 minutes at room temperature, to allow the siRNA-lipid complexes 
to form. The siRNA-lipid complex was then added directly into the serum free media 
incubating the cells in the 6-well plate, and incubated for 6 hours at 37°C 5% CO2. 
After the 6 hours transfection time, fresh media added.  The cells were incubated for 
a further 12-96 hours. Cells were assayed by RT-PCR (section II.3), to assess for 
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Table IV.1; HDAC7 siRNA nucleotide sequence - HDAC7 siRNA targets HDAC7 mRNA 
between 3040-3057 base pairs.  
 
IV.2.1.1 Detection of HDAC7 gene silencing for RT-PCR 
Primers to detect the silence of the HDAC7 gene expression in H460 cells were cus-
tom designed using the primer blast tool on the National Center for Biotechnology 
Information (NCBI) and purchased from Invitrogen (UK). Primer sequences are shown 
in table II.1. 
IV.2.2 Determination of MMP-10 selective enzyme activity in the presence/ab-
sence of HDAC7 
H460 cells were plated at a density of 4x105 cells per well in a 6 well plate and incu-
bated in complete media for 24 hours. To compare the involvement of HDAC7 upon 
MMP-10 activity, cells were treated with either HDAC7 siRNA (100nM) (concentra-
tion optimised in section IV.2) or the class IIa selective inhibitor 401940 (1μM). To 
assess the levels of active endoprotease enzymes present in cell media, aliquots of 
media were removed at various time points over the duration of the time course (24-
96h). The fluorometric enzyme assay was performed in a 96 well plate by incubating 
10μl of media with 50μg of fluorogenic substrate M-2110(Mca-Arg-Pro-Lys-Pro-Val-
Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂) in 80μl of MMP activity buffer (100 mM Tris-HCl pH 
7.6, 10 mM CaCl2, 100 mM NaCl, 0.16% v/v Brij-35); total reaction volume of 100μl. 
 HDAC7 siRNA Nucleotide sequence (5’->3’)  





GGAAGAACCUAUGAAUCUCtt GAGAUUCAUAGGUUCUUCCtc 538bp 
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Fluorescence was measured (excitation = 325 nm; emission = 393 nm) over a 600 
minute incubation period at 37°C. For each sample, the relative activity of the initial 
linear enzyme activity was calculated, and activity expressed as change in fluores-
cence per hour per 4x105 cells. The reproducibility and reliability of the assay were 
determined using samples obtained from three independent experiments. 
 
IV.2.3 Determination of cell viability upon HDAC7 inhibition, using the MTT assay 
H460 cells were seeded in 96-well plates (250 cells/well, optimised in figure III.3) and 
incubated for 24 hours (37°C in humidified atmosphere of 5% CO2 and 95% air), me-
dia removed and replaced with fresh media. HDAC7-selective inhibitor was prepared 
as a 10mM stock solution and added to the 96-well plate by serial dilution at a final 
concentration of 1pM-10μM and incubated for 12-96 hours (37°C in humidified at-
mosphere of 5% CO2 and 95% air). After the designated incubation time, an MTT was 
carried out, as described in section III.2.5. 
 
IV.2.4 Determination of cell viability upon HDAC7 inhibition, using xCELLigence as-
say 
H460 cells were seeded into wells of the E-plate at a density of 1000 cells/well (opti-
mised in figure III.2), the RTCA DP software was set up as described in section II.2.4, 
and incubated for 24 hours (37°C in humidified atmosphere of 5% CO2 and 95% air), 
media removed and replaced with fresh media. HDAC7-selective inhibitor was pre-
pared as a 10mM stock solution and added to the E-plate at a final concentration of 
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1μM (optimised non-toxic dose, up to 48 hours in figure IV.8) and incubated for 48 
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IV.3 Results 
IV.3.1. Lack of cytotoxicity of HDAC7 siRNA on NSCLC in vitro 
Initially a cell viability assay in the form of an MTT was carried out to determine a 
range of appropriate non-toxic doses to use in vitro (figure IV.1). Cells were given a 
single dose of an increasing concentration of HDAC7 siRNA (between 0.39-100nM). 
Survival was assessed at 72 hours, with no toxicity observed at any dose over the 72 
hour exposure period. 
 
IV.3.1.2 Identification of HDAC7 siRNA concentrations required for optimal retar-
dation of HDAC7 gene expression 
To determine the optimal conditions for silencing the HDAC7 gene in NSCLC, H460 
cells were treated with HDAC7 siRNA at a range of non-toxic working concentrations; 
between 1-100nM over a time course of 12-72 hours (figure IV.2).  
A concentration and time dependant silencing of the HDAC7 gene was observed. At 
12 hours, no significant silence of HDAC7 gene expression was detected at any of the 
four siRNA concentrations (1-100nM) evaluated (figure IV.2A). At 24 hours, there was 
a significant change to gene expression with all four concentrations of siRNA, the 
greatest effect being between 10-100nM (p<0.01) (figure IV.2B). At 48 hours, the 
highest concentration of siRNA; 100nM was the only concentration effecting a 
change on HDAC7 gene expression (figure IV.2C). At 72 hours, the effect of HDAC7 
siRNA upon HDAC7 gene expression showed no significant difference to that ob-
served in the absence of siRNA (figure IV.2D). No significant difference in expression 
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of the housekeeping gene, GAPDH, was observed at any of the time points, indicating 
comparability between studies. Consequently, 100nM was chosen as the optimal 
non-toxic dose for subsequent experiments.  
 
IV.3.1.3 HDAC7 gene expression relates to MMP-10 gene expression in H460 
NSCLC cell model in vitro 
To investigate a relationship between HDAC7 gene expression and the gene expres-
sion of MMP-10 in NSCLC, H460 cells were treated with the optimised concentration 
(100nM) of siRNA to suppress HDAC7 gene expression in the cells. Following success-
ful silencing of HDAC7 at 24 hours (P<0.01) and 48 hours (P<0.05) (figure IV.4A), the 
levels of MMP-10 gene expression were significantly increased at both 24 hours 
(P<0.01) and 48 hours (P<0.05) compared to control (figure IV.4B).  
 
IV.3.1.4 Relationship between HDAC7 gene expression and regulation of MMP-10 
proteolytic activity in H460 NSCLC cells model 
MMP-10 can exist as both an inactive proenzyme and as an active enzyme. To evalu-
ate whether HDAC7 expression has an effect on functional (active) levels of MMP-
10, the proteolytic cleavage of the MMP-selective substrate, M2110, was determined 
following knockdown of HDAC7 gene expression. Increased MMP-10 activity was ob-
served at 24 (P<0.05) and 96 hours (P<0.05) after siRNA-mediated knockdown of 
HDAC7 (figure IV.6), suggesting an inverse relationship between expression of HDAC7 
and MMP-10 proteolytic activity. 
122 | P a g e  
 
 
Figure IV.1 Survival curves obtained for H460 cells after 72 hours exposure to a single 
dose of HDAC7 siRNA, at a range of concentrations (100nM to 0.39nM). MTT assays 



























































Figure IV.2 Effect of increasing concentrations of HDAC7 siRNA on the level of HDAC7 
mRNA in H460 model NSCLC - H460 cells were treated with increasing concentrations 
(1-100nM) of HDAC7 siRNA over a time course of 12-72 hours, assessed by semi-
quantitative RT-PCR. Gene expression of HDAC7 after A) 12 hours, B) 24 hours, C) 48 
hours and D) 72 hours, post treatment, control is shown in grey. Signal intensity was 
quantified by densitometry. Values are mean ± S.E. from three independent experi-
ments, statistical significance was calculated using a one-way ANOVA/Dunnet’s post 










































































































































Figure IV.3 HDAC7 gene expression in the presence of 100nM HDAC7 siRNA over a 
time period of 12-72 hours in H460 model NSCLC. HDAC7 relative gene expression 
following exposure of H460 cells to 100nM HDAC7 siRNA. Data is summarised from 
figure IV.2 and illustrates 100nM siRNA as the optimal dose for silencing HDAC7 gene 
expression. Values are mean ± S.E. from three independent experiments, statistical 


























































Figure IV.4 Knockdown of HDAC7 gene expression induces increased expression of 
MMP-10 gene - H460 cells were treated with HDAC7 siRNA (100nM) over a time 
course of 12-48 hours. Gene expression of A) HDAC7 and B) MMP-10, post treatment, 
determined by RT-PCR. Signal intensity was quantified by densitometry. Values are 
mean ± S.E. from three independent experiments, *p<0.05, **p<0.01, ***p<0.001, 













































































































Figure IV.5 Effect of HDAC7 siRNA on the level of HDAC7 and mRNA in NSCLC - HDAC7 
(green) and MMP-10 (black) relative gene expression following exposure of H460 
cells to 100nM HDAC7 siRNA over 12-48h. Data is summarised from figure IV.4 and 
illustrates a reduction in HDAC7 gene expression following knockdown results in an 































































Figure IV.6 Knockdown of HDAC7 gene expression results in increased levels of ac-
tive MMP-10 
To assess the levels of active proteolytic enzyme, medium was removed following 
treatment of H460 cells with a single dose of HDAC7 siRNA (100nM) over a time 
course (0-96h). Activity levels were determined by measuring cleavage of the fluoro-
genic substrate M-2110 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂) 
with selectivity for MMP-10. Values are mean ± S.E. from three independent experi-
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IV.3.2 Involvement of HDAC7 enzymatic activity in regulation of MMP-10 
To determine whether it is the enzymatic activity of HDAC7 or the physical presence 
of HDAC7 which regulates the gene expression of MMP-10 in NSCLC, H460 cells were 
treated with the class IIa selective inhibitor; 401940.  
IV.3.2.1 Evaluation of cytotoxicity of class IIa selective inhibitor against H460 
NSCLC cell line in vitro 
1μM of 401940 was determined as the optimal dose to use for investigating the ef-
fect of MMP-10 post treatment of the class IIa HDAC inhibitor (figure IV.7). 
To confirm the lack of toxicity and mitigate any cytological response of the inhibitor 
and to examine the effects elicited by the class IIa selective HDAC inhibitor on the 
growth kinetics of the cell, the xCELLigence assay was used. The non-toxic dose; 1μM 
(determined by MTT assay) demonstrated no overall changes in cell index relative to 
control. The lack of significant modulation of cell index indicates the inhibitor does 
not affect attachment of the cells to the plate, induce a hyper- or hypoplastic re-
sponse, or cause a detectable change in cellular morphology. Consequently, the in-
hibitor can inhibit HDAC7 enzymatic activity (EC50 HDAC7 = 30nM; Burli et al., 2013) 
but does not affect cellular characteristics at a concentration of 1μM in vitro, sup-
porting its use to determine the role played by HDAC7 enzymatic activity upon MMP-




















Figure IV.7 Concentration and time dependant cytotoxicity of class IIa HDAC inhibitor 
401940 against H460 cell line in vitro - Survival curves obtained for H460 cells after 
A) 12 hours, B) 24 hours, C) 48 hours and D) 96 hours exposure to a single dose of 
the class IIa selective inhibitor; 401940, at a range of concentrations (10,000nM to 
0.001nM). Data representative of the mean ± S.E. of 3 independent experiments. 
 








Time (hours) Minimum toxic dose Cytotoxic IC50 
12 >10µM >10μM 
24 1µM >10μM 
48 1µM 5μM 
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Figure IV.8 Lack of cytological effect of non-toxic concentration (1μM) of the class IIa 
HDAC inhibitor, 401940, obtained by xCELLigence RTCA. The black arrow indicates 














1μM class IIa HDAC in-
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IV.3.2.3 Inhibition of HDAC7 enzyme activity does not affect MMP-10 gene ex-
pression in NSCLC in vitro 
To investigate whether HDAC7s enzymatic activity is required to regulate the gene 
expression of MMP-10 in NSCLC, H460 cells were treated with the optimal non-toxic 
dose (1μM) of the class IIa selective inhibitor; 401940 over a time course (12-48 
hours). After exposure to the inhibitor, there was no significant differential MMP-10 
expression relative to control (figure IV.9B), implying HDAC7-mediated regulation of 
MMP-10 is independent of HDAC7 activity.  
 
IV.3.2.4 Inhibition of HDAC7 enzymatic activity does not affect MMP-10 proteo-
lytic activity 
Because MMP-10 can exist as both an inactive proenzyme and as an active enzyme, 
the effect of inhibition of HDAC7 enzyme activity upon proteolytic activity of MMP-
10 was assessed in NSCLC cells in vitro.  
The inhibition of HDAC7 enzymatic activity using the class IIa selective inhibitor, 
401940, did not retard the proteolytic activity of MMP-10 in the H460 NSCLC cell line 
model in vitro. This further supports the lack of involvement of HDAC7 enzymatic 


















Figure IV.9 The selective class IIa inhibitor; 401940, does not affect levels of HDAC7 
and MMP-10 mRNA in NSCLC. H460 cells were treated with 1μM of the class IIa se-
lective inhibitor; 401940 over a time course of 12-48 hours. Gene expression of A) 
HDAC7 and B) MMP-10, after exposure to the selective inhibitor, determined by RT-
PCR. Signal intensity was quantified by densitometry. Values are mean ± S.E. from 



































































































Figure IV.10 Inhibition of HDAC7 enzymatic activity does not affect MMP-10 activity 
in H460 NSCLC cells in vitro 
The levels of active MMP-10 proteolytic enzyme, in the presence of the class IIa se-
lective inhibitor; 401940 (1μM), was determined over a time course (24-96h). Activity 
levels were determined by measuring cleavage of the fluorogenic substrate M-2110 
(Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂) with selectivity for MMP-













































134 | P a g e  
 
IV.3.3 Discussion 
The secreted endopeptidase; MMP-10, is involved in degradation of the ECM and is 
thought to play a central role in the regulation of vascular development (Chang et al., 
2006). Elevated MMP-10 levels have shown to induce remodelling of the vascular 
extracellular matrix, capillary tube regression and vascular collapse in vivo (Chang et 
al., 2006). MMP-10 expression has been shown to be repressed in vivo by HDAC7 in 
the developing vasculature to maintain vascular integrity (Chang et al., 2006). High 
levels of proteolytically active MMP-10 have been observed in human primary 
NSCLC, and recurrent NSCLC, regardless of the histologic type (Cho et al., 2004; Gill 
et al., 2004). Recently MMP-10 has been linked to cancer stem cells, Justilien and 
colleagues reported MMP-10 is highly expressed in lung cancer stem cells (CSC) (Jus-
tilien et al., 2012). Furthermore, MMP-10 expression is also postulated to be elevated 
due to its involvement during endothelial restructuring required for angiogenesis. In 
this context, MMP-10 is involved with vessel formation and stabilization rather than 
contributing to the invasive nature of tumours, an action supported by published 
studies (Heo et al., 2010). Preliminary data carried out by Gill et al., (chapter 1, figure 
I.3) showed that overexpression of MMP-10 in a human NSCLC tumour model did not 
affect cellular proliferation in vitro, but caused significant retardation of tumour 
growth in vivo, further supporting this role for MMP-10 in NSCLC. The aim of the work 
in this chapter was to determine whether the expression and activity of HDAC7 is 
involved in the regulation of MMP-10 in NSCLC.  
The silencing of HDAC7 in H460 cells using siRNA resulted in a time-dependent in-
crease in MMP-10 gene expression. The increase in MMP-10 gene expression in re-
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sponse to inhibition of HDAC7 gene expression, indicating an inverse relationship be-
tween these factors, was also accompanied by an increase in proteolytic activity of 
MMP-10. This elevation of MMP-10 activity occurred post-transcriptionally, support-
ing regulation at gene level. This result suggested that the proteolytic activity of 
MMP-10 is significantly increased along with its expression upon HDAC7 repression, 
reinforcing the involvement of HDAC7 in the regulation of MMP-10 (Herbst et al., 
2008). To determine whether the existence of HDAC7 or its enzymatic activity is re-
sponsible for the effects upon MMP-10, inhibition of HDAC7 activity was evaluated. 
However, the inhibition of HDAC7s enzymatic activity using the selective IIa inhibitor 
did not cause a change in MMP-10 gene expression, compared to control. In addition, 
inhibition of HDAC7 enzymatic activity did not alter levels of proteolytically active 
MMP-10. This suggests that although HDAC7 is central to MMP-10 expression the 
activity of HDAC7 has no influence on the regulation of MMP-10 in vitro unlike the 
class I HDACs which directly enzymatically regulate gene expression. The class IIa 
HDACs; -4, -5, -7 and -9, are reported to have a low deacetylase activity against acet-
ylated histones (Haberland et al., 2009). Furthermore, HDAC7 has been reported to 
recruit class I HDACs through its C-terminal HDAC domain, with its enzymatic activity 
dependent upon being bound to the class I HDAC; HDAC3 (Fischle et al., 2001), in 
agreement with other class IIa HDACs, although predominantly localised in the cellu-
lar nucleus HDAC7 can also locate in the cytoplasm, suggesting nucleoplasmic shut-
tling of this enzyme occurs (Kao et al., 2001). In the cytoplasm, HDAC7 is not bound 
to HDAC3 and is therefore enzymatically inactive with the converse apparent in the 
nucleus (Fischle et al., 2001). The interaction between HDAC7 and HDAC3 is in itself 
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indirect with these two HDACs being co-recruited by the transcriptional co-re-
pressors SMRT and N-CoR, which serve as crucial mediators of HDAC7 activity by sim-
ultaneously binding HDAC7 and HDAC3 via two repressor domains (Fischle et al., 
2001).  
Therefore, although HDAC7 is required for MMP-10 activity, as shown in this study 
and those investigating vascular development, it is not as straightforward as first pos-
tulated and is neither a direct acetylation effect nor a ‘conventional’ HDAC pathway. 
It is well established that HDAC7 is regulated post-translationally. The class IIa HDACs 
possess a conserved C-terminal catalytic HDAC domain and interact with myocyte 
enhancer factor 2 (MEF2) transcription factors through an N-terminal 17-amino acid 
motif. This interaction leads to the recruitment of class IIa HDACs to select promot-
ers, where MEF2 is bound, resulting in the repression of its transcriptional activity. 
The repressive activity of class IIa HDAC; HDAC7 is tightly regulated by nucleoplasmic 
shuttling and by their phosphorylation dependant association with the intracellular 
14-3-3 proteins. Phosphorylation of conserved residues in the N-terminal regions of 
HDAC7 in response to cellular signals leads to interaction with 14-3-3 proteins, dis-
sociation of the class IIa HDAC-MEF2 complexes and a conformational change culmi-
nating in export from the nucleus (Parra et al., 2004). However, this study implies 
another potential mechanism for HDAC7 in the regulation of MMP-10, HDAC7 could 
act as transporter, shuttling a class I HDAC, potentially HDAC3 into the nucleus where 
it acts upon the control of MMP-10 expression and activity, indicative in the im-
portance of HDAC7 presence but not activity in the regulation of MMP-10. In this 
mechanistic model, although HDAC7 presence is important for regulation of MMP-
10 expression and activity its role would be to ‘mobilise’ gene regulators, specifically 
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HDAC3, with these latter proteins being the drivers of MMP-10 expression. In terms 
of NSCLC and the involvement of MMP-10 therein, a much larger and more complex 
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Chapter V – Class I HDAC-mediated regulation of MMP-10 expression in NSCLC 
V.1 Introduction 
Class I HDACs, which include; HDAC1, -2, -3 and -8 are ubiquitously expressed in tis-
sues and are the most thoroughly investigated with respect to function (Fischle et al., 
2001; Hayashi et al., 2010). They are known to have a high deacetylase activity and 
control the deacetylation state of lysine sidechains in histone tails, promoting chro-
matin condensation and consequent transcriptional repression (Chang et al., 2006; 
Watson et al., 2016). The class I HDACs regulate a number of genes by directly inter-
acting with transcription factors; including Ef2, Stat3, p53 and NF-Kb (Delcuve et al., 
2012). Deletion of these enzymes individually leads to deregulation of a limited set 
of genes, further supporting their involvement in transcription regulation, with a role 
in cell proliferation and survival (Reichert et al., 2012; Delcuve et al., 2012).  
Members of the class I HDACs (all except HDAC8) have been found to form several 
large multiplexes with other proteins, each with particular biological functions, offer-
ing a further way they regulate gene expression (Fischle et al., 2001). The formation 
of these complexes are targeted to specific genomic regions by interactions with DNA 
binding factors that include transcription factors, nuclear receptors, and other epi-
genetic modifier genes, such as methyl-binding proteins (MBDs), DNA methyl trans-
ferases (DNMTs) and histone methyl transferases (HMTs) (Fischle et al., 2001; Ropero 
& Esteller, 2007).  
HDAC1 and -2 are close homologues and exclusively nuclear, they are known to form 
homo- and heterodimers between each other, which presumably allows them to act 
together or separately from each other, and it is thought that the dimer is required 
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for HDAC activity (Delcuve 2012). They are found together in repressive complexes 
such as sin3, NuRD, CoREST and PRC2 complexes, which are recruited to chromatin 
regulatory regions by transcription factors and have diverse, often cell-specific roles 
(Haberland et al., 2011; Gallinari et al., 2007; Delcuve et al., 2012). These complexes 
are recruited to chromatin through interaction with repressive transcription factors 
or other silencing co-factors and their enzymatic activity shows significant enhance-
ment when incorporated into their cognate co-repressor complexes (Watson et al, 
2016). There is extensive evidence to support the activity of these nuclear-restricted 
HDACs as being exclusively toward histone modulation and gene expression (Galli-
nari et al., 2007). 
HDAC3, another class I HDAC, unlike HDAC1 and -2, has been found to be present in 
both the nucleus and cytoplasm, suggesting nucleoplasmic shuttling of this enzyme. 
Like HDAC1 and -2 it to is found in distinct complexes, such as the two highly related 
complexes nuclear receptor corepressor (NCoR or NCOR1) and silencing mediator of 
retinoic acid and thyroid hormone receptor (SMRT) (Haberland et al., 2011). These 
nuclear corepressors are regulated by different kinase pathways and play different 
roles in development. It is noteworthy that repression by NCoR/SMRT is an integral 
phase of the cyclical process that is the transcriptional activation of genes controlled 
by liganded receptors (Delcuve et al., 2012). NCoR/SMRT repression is necessary to 
prime chromatin for subsequent transcription initiation. Besides its role in transcrip-
tional control, the HDAC3-NCoR-SMRT axis is critical to the maintenance of hetero-
chromatin content and genomic stability (Delcuve et al., 2012). Deregulated func-
tions of NCor and SMRT have been observed in many types of cancers; including 
breast and prostate (Wong et al., 2014).  
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In addition to their central role in HDAC3 activity and gene expression, NCoR and 
SMRT also interact with class IIa HDACs, which have minimal deacetylase activity, but 
are believed to recruit NCoR/SMRT HDAC3 activity to distinct promoters, such as my-
ocyte enhancer factor 2 (MEF2) (Martin et al., 2007). The class IIa HDACs are signal 
transducers characterised by the presence in their regulatory N-terminal domains of 
two or three conserved serine residues subject to reversible phosphorylation 
(Delcuve et al., 2012). Phosphorylation leads to the binding of the 14-3-3 proteins, 
the nuclear export of HDACs and the derepression of their target genes. A range of 
kinases and phosphatases acting downstream of diverse biological pathways have 
been shown to regulate the nucleocytoplasmic trafficking of class IIa HDACs (Delcuve 
et al., 2012).  
For instance, HDAC7 is phosphorylated by PKD1 and this is shown to facilitate cyto-
plasmic retention of this HDAC and subsequently its functional translocation activity 
(Parra et al., 2005). In the context of vascular development and particularly angio-
genesis, VEGF the driving factor for this process directly regulates HDAC7 as demon-
strated in chapter IV, although HDAC7 is important for MMP-10 expression and ac-
tivity, this involves a mechanism dependent of HDAC7 enzymatic activity but depend-
ent upon HDAC7 presence. 
One viable explanation is that the class IIa HDAC; HDAC7 may be responsible for re-
cruiting class I HDACs, which allows them to elicit their repressive activity against 
MMP-10 in NSCLC. Such a collaborative role between HDAC7 and HDAC3 has already 
been shown in several studies, indicating a close relationship between HDAC7 and 
HDAC3 in the control of biological functions (Fischle et al., 2002; Fischle et al., 2001). 
For instance, in cancer cells HDAC3 and HDAC7 collaboratively suppress expression 
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of autotaxin, a secreted glycoprotein responsible for production of lysophosphatidic 
acid (LPA) involved in cancer progression, including NSCLC (Li et al., 2014). Whereas 
down-regulation of HDAC3 facilitates histone acetylation in the ATx promotor, con-
comitant down-regulation of HDAC7 was required to induce ATx expression (Li et al., 
2014). These data suggest HDAC3-mediated acetylation of ATx is sufficient and the 
presence of HDAC7 is needed to ‘modulate’ HDAC3 activity (Fischle et al., 2002; Fishel 
et al., 2001). Therefore, it is highly plausible that such a function could exist in the 
case of MMP-10, with HDAC3 facilitated by HDAC7 being the actual regulatory pro-
cess. 
 
V.1.1 Aims and objectives 
The aim of this chapter is to build upon the confirmation of the involvement of 
HDAC7 in the regulation of MMP-10 expression and activity in NSCLC in vitro and 
further define the mechanistic basis of this process. In particular this chapter will ad-
dress the existence of a dynamic relationship between HDAC7 and the class I family 
member HDAC3 in the regulation of MMP-10. In order to evaluate such a mechanism, 
the effect of regulating activity and presence of HDACs and more specifically HDAC 
sub-families and individual HDACs upon MMP-10 expression and activity in the in 
vitro NSCLC model system will be evaluated. 
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V.2 Methods 
V.2.1 Determination of cell viability upon HDAC inhibition, using the MTT assay 
H460 cells were seeded in 96-well plates (250 cells/well, optimised in figure III.3) and 
incubated for 24 hours (37°C in humidified atmosphere of 5% CO2 and 95% air), me-
dia removed and replaced with fresh media. The range of HDAC inhibitors were pre-
pared as a 10mM stock solution and added to the 96-well plate by serial dilution at a 
final concentration of 1pM-10μM and incubated for 12-96 hours (37°C in humidified 
atmosphere of 5% CO2 and 95% air). After the designated incubation time, an MTT 
was carried out, as described in section III.2.5. 
 
V.2.2 Determination of cell viability upon HDAC inhibition, using xCELLigence as-
say 
H460 cells were seeded into wells of the E-plate at a density of 1000 cells/well (opti-
mised in figure III.2), the RTCA DP software was set up as described in section II.2.4, 
and incubated for 24 hours (37°C in humidified atmosphere of 5% CO2 and 95% air), 
media removed and replaced with fresh media. The range of HDAC inhibitors were 
prepared as a 10mM stock solution and added to the E-plate at varying final concen-
trations (previously optimized by MTT assay), and incubated for 48 hours (37°C in 
humidified atmosphere of 5% CO2 and 95% air). 
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V.2.3 Knockdown of HDAC3 expression in H460 NSCLC cells with siRNA 
Two sets of double stranded small-interference RNA (siRNA) for HDAC3 (sequence, 
Table V.1) (Ambion, UK), were reconstituted to a stock concentration of 100μM in 
sterile dH2O. For in vitro cell studies, siRNA was further diluted into 250μl serum free 
media; OptiMEM, at a range of working concentrations (50-200nM).  
H460 cells were grown in 6 well plates (4x105 cells per well) (as described in section 
II.2), media was removed from the cells, the cells washed in HBSS, and serum free 
media added to the cells. The transfection agent Lipofectamine 2000 (Invitrogen, 
UK), was reconstituted at a 1:35 ratio into OptiMEM, to a final volume of 250μl. The 
Lipofectamine (250μl) and siRNA (250μl) solutions were combined and the mixture 
incubated for 15 minutes at room temperature, to allow the siRNA-lipid complexes 
to form. The siRNA-lipid complex was added directly into the serum free media and 
incubated for 6 hours at 37°C 5% CO2. After the 6 hours transfection time, fresh me-
dia was added and the cells were incubated for a further 12-96 hours. Cells were 
assayed for RT-PCR, see section II.3 for details. 
 
Table V.1; HDAC3 siRNA nucleotide sequence - HDAC3 siRNA targets HDAC3 mRNA 
between 605-619bp 
 
 HDAC3 Nucleotide sequence (5’->3’)  




GCUUUCUACCUCACUGACCtt GGUCAGUGAGGUAGAAAGCtt 511bp 
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V.2.3.1 Detection of HDAC3 gene silencing for RT-PCR 
Primers to detect the silence of the HDAC3 gene expression in H460 cells were cus-
tom designed using the primer blast tool on the National Center for Biotechnology 
Information (NCBI) and purchased from Invitrogen (UK). Primer sequences are shown 
in table II.1. 
 
V.2.4 Detection of HDAC3 gene silencing on HDAC3 protein expression 
H460 cells were plated at a density of 4X106 cells per well in a 6 well plate, and incu-
bated in complete media for 24 hours (37°C in humidified atmosphere of 5% CO2 and 
95% air). HDAC3 gene expression was silenced using HDAC3 siRNA, as previously de-
scribed and optimised in section V.2.3. Following knockdown, protein was extracted 
and quantified (as described in section II.5.2), samples prepared and proteins frac-
tionated using SDS-PAGE (see section II.5.3 for details). Proteins were transferred to 
a membrane and probed with antibodies to detect human HDAC3, as described in 
section II.5.4/II.5.5 (see table II.3 for antibody details and concentrations). 
 
V.2.5 Determination of MMP-10 selective enzyme activity in the presence/ab-
sence of HDAC7 
H460 cells were plated at a density of 4x105 cells per well in a 6 well plate and incu-
bated in complete media for 24 hours. To compare the effect of expression of activity 
upon MMP-10 activity, cells were treated with either HDAC3 siRNA (50nM) or a class 
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I HDAC inhibitor (MS275, 1μM). To assess the levels of active endoprotease enzymes 
present in cell media, aliquots of media were removed at various time points over 
the duration of the time course (24-96h). The fluorometric enzyme assay was per-
formed in a 96 well plate by incubating 10μl of media with 50μg of fluorogenic sub-
strate M-2110(Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂) in 80μl of 
MMP activity buffer (100 mM Tris-HCl pH 7.6, 10 mM CaCl2, 100 mM NaCl, 0.16% v/v 
Brij-35); total reaction volume of 100μl. Fluorescence was measured (excitation = 
325 nm; emission = 393 nm) over a 600-minute incubation period at 37°C. For each 
sample, the relative activity of the initial linear enzyme activity was calculated, and 
activity expressed as change in fluorescence per hour per 4x105 cells. The reproduc-
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V.3 Results 
V.3.1.1 Cytotoxicity of the pan inhibitor Trichostatin A on NSCLC in vitro 
For up to 24 hours; 100nM of TSA was determined as the optimal dose to use for 
investigating the effect of MMP-10 post treatment of the HDAC pan inhibitor (figure 
V.1), with an IC50 value of >10µM (table V.2). 
To confirm lack of toxicity and mitigate against any drug induced cytological effects 
and to examine the effects elicited by TSA, at a non-toxic concentration for 24-hour 
drug exposure on the growth kinetics of the cell, the xCELLigence assay was used. 
The non-toxic dose; 100nM (determined by MTT assay) demonstrated no overall 
changes in cell index relative to control (figure V.2). This indicates at this non-toxic 




























Figure V.1 The pan-HDAC inhibitor induces dose and time-dependant cytotoxicity 
against H460 NSCLC in vitro. Survival curves obtained for H460 cells after A) 12 hours, 
B) 24 hours, C) 48 hours and D) 96 hours exposure of the HDAC pan inhibitor; TSA, at 
a range of concentrations (1000nM to 0.001nM). Data representative of the mean ± 
SD of 3 independent experiments. 
 
Table V.2; Summary of minimum toxic dose of TSA for 12-96h 
 
Time (hours) Minimum toxic dose Cytotoxic IC50 
12 >10µM >10μM 
24 1µM >10μM 
48 1nM 5nM 
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Figure V.2 Lack of significant cytological effect of 100nM TSA against H460 NSCLC in 
vitro, obtained by xCELLigence RTCA. The black arrow indicates the time of drug ad-
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V.3.1.3 Inhibition of class I and II HDACs activity induces expression of MMP-10 
gene in NSCLC 
To investigate the effect on MMP-10 expression following inhibition of all the HDACs 
in NSCLC, H460 cells were treated with the optimised concentration (100nM) of the 
pan inhibitor; TSA over a time course (12 and 24 hours). After exposure to the inhib-
itor, MMP-10 expression significantly increased at both 12 hours (p<0.05) and 24 
hours (p<0.01), compared to control (figure V.3B). 
 
V.3.1.4 Inhibition of HDACs induces MMP-10 proteolytic activity in H460 NSCLC 
cells model 
Because MMP-10 can exist as both an inactive proenzyme and as an active enzyme, 
MMP activity following treatment upon pan inhibition was assessed. Using the MMP-
selective substrate, M2110, activity relating to MMP-10 activity can be evaluated. 
Increased MMP-10 activity was observed at 48 hours (P<0.001), suggesting a rela-






















Figure V.3 The HDAC pan inhibitor; TSA, inhibits expression of HDAC7 mRNA and in-
duces MMP-10 mRNA expression in NSCLC. H460 cells were treated with 100nM of 
the HDAC pan inhibitor; TSA over a time course of 12 and 24 hours. Gene expression 
of A) HDAC7 and B) MMP-10, post treatment, determined by RT-PCR. Signal intensity 
was quantified by densitometry. Values are mean ± S.E. from three independent ex-

























































































Figure V.4 The induction of MMP-10 activity by inhibition of HDAC enzymes in H460 
NSCLC model 
To assess the levels of active proteolytic enzyme, medium was removed following 
treatment of H460 cells with a single dose of TSA (100nM) over a time course (0-96h). 
Activity levels were determined by measuring cleavage of the fluorogenic substrate 
M-2110 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂) with selectivity 
for MMP-10. Values are mean ± S.E. from three independent experiments, p<0.001 
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V.3.2 Cytotoxicity of class I HDAC inhibitor on NSCLC in vitro 
1μM of MS275 was determined as the optimal dose to use, for investigating the ef-
fect of MMP-10, post treatment of the class I HDAC inhibitor (figure V.5). 
To confirm lack of toxicity and identify any time-dependent drug-induced cytological 
effects and to examine the effects elicited by MS275 on the growth kinetics of the 
cell, the xCELLigence assay was utilised. The non-toxic dose; 1μM (determined by 
MTT assay) demonstrated no overall changes in cell index relative to control (figure 
V.6). This indicates that inhibition of class I HDACs does not alter cell proliferation, 





























Figure V.5 The class I HDACi induces concentration of time-dependent cytotoxicity. 
Survival curves obtained for H460 cells after A) 12 hours, B) 24 hours, C) 48 hours and 
D) 96 hours exposure, to a single dose of the class I HDAC inhibitor; MS275, at a range 
of concentrations (1000nM to 0.001nM). Data representative of the mean ± SD of 3 
independent experiments. 
 








Time (hours) Minimum toxic dose Cytotoxic IC50 
12 >10µM >10μM 
24 1µM 5μM 
48 10nM 50nM 
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Figure V.6 Lack of significant cytological effect of 1μM class I HDACi; MS275 against 
H460 in vitro, obtained by xCELLigence RTCA. The black arrow indicates the time of 
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V.3.2.2 Inhibition of class I HDAC activity reduces HDAC7 expression and induces 
MMP-10 gene expression in H460 NSCLC cells. 
To investigate the mechanism of which HDAC is responsible for regulating the gene 
expression of MMP-10 in NSCLC, H460 cells were treated with the optimal non-toxic 
dose (1μM) of the class I selective inhibitor; MS275. MS275 was used to inhibit the 
enzymatic activity of class I HDACs, over a time course of 12 and 24 hours. HDAC7 
gene expression significantly decreased after 12 (p<0.05) and although recovering 
toward control levels was still significantly reduced after 24 hours (p<0.001), post 
exposure to MS275 (figure V.7A). Conversely, MMP-10 gene expression was elevated 
5-fold 12 hours after MS275 treatment (p<0.05) (figure V.7B) and 2.5-fold after 24 
hours (figure V.7B).  
 
V.3.2.3 Exposure to the class I HDAC inhibitor MS275 does not significantly alter 
MMP-10 proteolytic activity in H460 NSCLC cells model 
Because MMP-10 can exist as both an inactive proenzyme and as an active enzyme, 
MMP activity following treatment of class I HDAC inhibition was assessed. Using the 
MMP-selective substrate, M2110, MMP-10 activity can be evaluated. Although 
MMP-10 proteolytic activity was elevated at 24 and 48 hours post-exposure to 
MS275 this was not shown to be significantly significant (figure V.8). Overall, no sig-
nificant difference in MMP-10 activity was expressed between control and treated 
cells over the time course (24-96h) (figure V.8). 
 
 














Figure V.7 The selective class I HDAC inhibitor; MS275, reduces HDAC7 mRNA and 
increases MMP-10 mRNA in NSCLC. H460 cells were treated with 1μM of the class I 
selective HDAC inhibitor; MS275 over a time course of 12 and 24 hours. Gene expres-
sion of A) HDAC7 and B) MMP-10, after exposure to the selective inhibitor, deter-
mined by RT-PCR. Signal intensity was quantified by densitometry. Values are mean 
± S.E. from three independent experiments, *p<0.05, **p<0.01, compared by un-


















































































































Figure V.8 Lack of significant effect of inhibiting class I HDAC activity on MMP-10 
enzymatic activity in H460 NSCLC model 
To assess the levels of active proteolytic enzyme, medium was removed following 
treatment of H460 cells with a single dose of MS275 (1μM) over a time course (0-
96h). Activity levels were determined by measuring cleavage of the fluorogenic sub-
strate M-2110 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂) with selec-












































158 | P a g e  
 
V.3.3 Evaluation of cytotoxicity of HDAC3 selective inhibitor on NSCLC in vitro 
1μM of MI192 was determined as the optimal dose to use for investigating the effect 
of MMP-10, post treatment of the HDAC3-selective inhibitor. 
To confirm lack of toxicity and identify any drug-induced modulation of cell prolifer-
ation, attachment or morphology and to examine the effects elicited by MI192 on 
the growth kinetics of the cell the xCELLigence assay was used. The non-toxic dose; 
1μM (determined by MTT assay) again showed no overall changes in cell index, in-































Figure V.9 The HDAC3-selecitve inhibitor induces concentration and time dependent 
cytotoxicity. Survival curves obtained for H460 cells after A) 12 hours, B) 24 hours, C) 
48 hours and D) 96 hours exposure to a single dose of the class I selective HDAC3 
inhibitor; MI192, at a range of concentrations (1000nM to 0.001nM). MTT assays 
were performed as described in II.2.5. Data representative of the mean ± SD of 3 
independent experiments.  
 








Time (hours) Minimum toxic dose Cytotoxic IC50 
12 >10µM >10μM 
24 1µM >10μM 
48 100nM 0.5μM 








































































































A) 12 hour exposure 24 hour exposure 
48 hour exposure 96 hour exposure 











Figure V.10 Lack of significant effect of 1μM HDAC3-selective inhibitor on H460 cell 
survival, attachment or morphology obtained by xCELLigence RTCA. The black arrow 
indicates the time of drug addition. H460 cells plated at 4000 cells per well and ob-
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IV.3.3.2 Inhibition of HDAC3 enzyme activity induces expression of MMP-10 but 
does not modulate HDAC7 expression in H460 NSCLC cells in vitro 
To investigate the mechanism of which HDAC is responsible for regulating the gene 
expression of MMP-10 in NSCLC, H460 cells were treated with the optimal non-toxic 
dose (1μM) of the HDAC3-selective inhibitor; MI192. Effects upon the expression of 
HDAC7 and MMP-10 in the cell were then evaluated. MMP-10 gene expression sig-
nificantly increased after 12 (p<0.001), 24 (p<0.001) and 48 hours (p<0.001) (figure 
V.11). Conversely, HDAC7 gene expression didn’t significantly change, post exposure 
to MI192 (figure V.11). 
 
V.3.3.3 Inhibition of HDAC3 activity induces MMP-10 proteolytic activity in H460 
NSCLC cells model 
Because MMP-10 can exist as both an inactive proenzyme and as an active enzyme, 
MMP activity following treatment of class I HDAC inhibition was assessed. Using the 
MMP-selective substrate, M2110, activity relating to MMP-10 activity can be evalu-
ated. MMP-10 proteolytic activity increased in a time dependant manner, MMP-10 



















Figure V.11 The HDAC3-selective inhibitor MI192 does not significantly change 
HDAC7 expression but induces MMP-10 mRNA in NSCLC. H460 cells were treated 
with 1μM of the selective HDAC3 inhibitor; MI192 over a time course of 12-48 hours. 
Gene expression of A) HDAC7 and B) MMP-10 after exposure to the selective inhibi-
tor, determined by RT-PCR. Signal intensity was quantified by densitometry. Values 
are mean ± S.E. from three independent experiments, ***p<0.001, compared by un-







































































































Figure V.12 Inhibition of HDAC3 activity induces MMP-10 enzymatic activity in H460 
NSCLC model 
To assess the levels of active proteolytic enzyme, medium was removed following 
treatment of H460 cells with a single dose of MI192 (1μM) over a time course (0-
96h). Activity levels were determined by measuring cleavage of the fluorogenic sub-
strate M-2110 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH₂) with selec-
tivity for MMP-10. Values are mean ± S.E. from three independent experiments, 
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V.3.4 Effect of HDAC3 presence upon HDAC7 expression and MMP-10 expression 
and activity 
IV.3.4.1 Lack of cytotoxicity of HDAC3 siRNA on NSCLC in vitro 
Initially a cell viability assay in the form of an MTT was carried out to determine a 
range of appropriate non-toxic doses of HDAC3 siRNA to use in vitro (figure V.13). 
Cells were given a single dose of an increasing concentration of HDAC3 siRNA (be-
tween 0.8-200nM). Cell survival was assessed at 72 hours. No cytotoxicity was ob-

















Figure V.13 Survival curves obtained for H460 cells after 96 hours exposure to a single 
dose of HDAC3 siRNA, at a range of concentrations (200nM to 80pM). MTT assays 
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V.3.4.2 Identification of HDAC3 siRNA concentrations required for optimal retar-
dation of HDAC3 expression 
To determine the optimal conditions for silencing the HDAC3 gene in NSCLC, H460 
cells were treated with HDAC3 siRNA at a range of non-toxic working concentrations; 
between 50-200nM over a time course of 12-72 hours (figure V.14).  
A concentration and time dependant silencing of the HDAC3 gene was observed. At 
12 hours no significant silence of HDAC3 gene expression was detected at any of the 
four siRNA concentrations (1-100nM) evaluated (figure V.14A). At 24 hours, there 
was a significant change to gene expression with all four concentrations of siRNA, 
with a similar effect for each (p<0.0001) (figure V.14B). At 48 hours, the two highest 
concentrations of siRNA (150 and 200nM) showed the largest significant change to 
gene expression (p<0.001) (figure V.14C). At 72 hours, the effect of HDAC3 siRNA 
upon HDAC3 gene expression showed no significant difference to that observed in 
the absence of siRNA (figure V.14D). No significant difference in expression of the 
housekeeping gene, GAPDH, was observed at any of the time points, indicating com-
parability between studies. Consequently, 50nM was chosen at the optimal non-toxic 



























Figure V.14 Effect of increasing concentrations of HDAC3 siRNA on the level of HDAC3 
mRNA messenger in NSCLC - H460 cells were treated with increasing concentrations 
(50-200nM) of HDAC3 siRNA over a time course of 12-72 hours. Gene expression of 
HDAC3 after A) 12 hours, B) 24 hours, C) 48 hours and D) 72 hours, post treatment, 
control is shown in grey, determined by RT-PCR. Signal intensity was quantified by 
densitometry. Values are mean ± S.E. from three independent experiments, *p<0.05, 
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Figure V.15 Effect of HDAC3 siRNA on the level of HDAC3 protein in NSCLC. H460 cells 
were treated with the optimal non-toxic dose of siRNA (50nM) over a time course of 
12, 24 and 48 hours. HDAC3 protein expression was determined by western blot anal-
ysis. A representative gel from each experiment is included below each graph. Signal 
intensity was quantified by densitometry. Values are mean ± S.E. from three inde-
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V.3.4.3 Silencing of HDAC3 expression results in inhibition of HDAC7 expression 
and induction of MMP-10 expression in NSCLC 
To investigate the mechanism by which HDAC3 regulates the gene expression of 
MMP-10 in NSCLC, H460 cells were treated with the optimal non-toxic dose (50nM) 
of siRNA to suppress the HDAC3 expression in the cells. siRNA knockdown of HDAC3 
gene and protein was significantly achieved at 24 hours (P<0.05), post treatment (fig-
ures V.15 and V.16A). MMP-10 gene expression in the presence of siRNA at 24 hours 
(p<0.05) showed a significant increase, as compared to vehicle treated cells only (fig-
ure V.16B). In addition, HDAC7 gene expression showed a significant decrease at 24 
(p<0.05) and 48 hours (p<0.05) post exposure to HDAC3 siRNA (figure V.16C). There-
fore, knockdown of HDAC3 expression regulates HDAC7 and MMP-10 expression. 
IV.3.4.4 Silencing of HDAC3 induces proteolytic activity of MMP-10 in NSCLC 
Because MMP-10 can exist as both an inactive proenzyme and as an active enzyme, 
MMP activity following treatment of HDAC3 siRNA was assessed. Using the MMP-
selective substrate, M2110, activity relating to MMP-10 activity can be evaluated. 
Increased MMP-10 activity was observed at 24 hours (P<0.05) (figure V.17), suggest-



























Figure V.16 Silencing of HDAC3 expression retards HDAC7 and induces MMP-10 ex-
pression in NSCLC. H460 cells were treated with the optimal non-toxic dose of siRNA 
(50nM) over a time course of 12-48 hours. Gene expression of A) HDAC3, B) MMP-
10 and C) HDAC7, post treatment, determined by RT-PCR. Signal intensity was quan-
tified by densitometry. Values are mean ± S.E. from three independent experiments, 















































































































Figure V.17 Knockdown of HDAC3 results in MMP-10 enzymatic activity in H460 
NSCLC model - To assess the levels of active proteolytic enzyme, medium was re-
moved following treatment of H460 cells with a single dose of HDAC3 siRNA (50nM) 
over a time course (0-96h). Activity levels were determined by measuring cleavage 
of the fluorogenic substrate M-2110 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-
Lys(Dnp)-NH₂) with selectivity for MMP-10. Values are mean ± S.E. from three inde-
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V.4 Discussion 
Histone acetylation modulates chromatin structure regulating DNA replication and 
gene transcription (Delcuve et al., 2012), through regulating access of transcription 
factors to chromatin structures (Delcuve et al., 2012; Ropero & Esteller, 2007). Addi-
tionally, HDACs form multiprotein corepressor complexes with nuclear receptors and 
transcription factors (eg HDAC3, -5 and -6 independently form complexes with the 
SMRT-NCoR complex) offering an alternative mechanism for gene regulation (Jayne 
et al., 2006). However, it is also now known HDACs are involved in the deacetylation 
not only of chromatin proteins but also deacetylation of non-histone proteins, which 
regulate important functions that, in turn, regulate cellular homeostasis (cell-cycle 
progression, differentiation, and apoptosis), non-histone targets include several 
transcription factors (eg HIF1α), regulatory proteins (eg MLP), tumour suppressor 
proteins (eg p53), and cellular structural proteins, such as α-tubulin (Martin et al., 
2007). Strong evidence appears to support deacetylation of non-histone proteins to 
be the action of the class II HDACs because they are known to have low deacetylase 
activity towards histones and class I HDACs being histone modifiers (Haberland et al., 
2009). 
 
Expression of the proteolytic enzyme; MMP-10 is known to play a key role in NSCLC, 
MMP-10 expression has previously been linked to the action of the class IIa HDAC; 
HDAC7 with roles suggested in tumour expansion and invasion, studies described in 
chapter IV suggested the expression but not the activity of HDAC7 was important in 
the regulation of MMP-10 in NSCLC in vitro, this suggests that the class IIa HDACs 
repressive activity may be independent of the catalytic domain of the deacetylase, 
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instead they have been reported to recruit class I HDACs through assembly into cog-
nate co-repressor complexes, for example interaction with the SMRT-N-CoR co-re-
pressors and they regulate transcription by bridging the enzymatically active com-
plexes and selective transcription factors independent of any intrinsic HDAC activity 
(Hudson et al., 2015; Fischle et al., 2002). The formation of these complexes between 
HDACs potentially offers rationale for the regulation of MMP-10, with HDAC7 being 
involved in formation of this complex and regulation of a class I HDAC and subse-
quently expression of MMP-10. 
Inhibition of all the family of HDACs in H460 cells using the pan inhibitor TSA, inhib-
iting both class I and II HDACs, caused a significant increase in MMP-10 expression 
and activity, suggesting the enzymatic activity of one or more HDACs is centrally in-
volved in the regulation of MMP-10 alongside an involvement for presence of 
HDAC7. The previous study results had confirmed class II HDAC activity was not re-
quired for MMP-10 expression, implying an additional involvement for class I HDACs. 
Inhibition of class I HDACs using the sub-family inhibitor MS275 resulted in an induc-
tion in gene expression of MMP-10 by up to 5-fold. However, no significant compar-
ative increase in MMP-10 proteolytic activity was detectable. This confirmed an in-
volvement for class I HDACs alongside HDAC7 in the control of MMP-10 expression 
in NSCLC. The lack of modulation of MMP-10 proteolytic activity with inhibition of 
class I HDACs is likely to be due to the level of MMP-10 expression in the cells, with 
MS275-induced expression being 5-fold compared to 120-fold with the pan-HDACi 
Trichostatin A, with the latter causing a significant increase in MMP-10 proteolytic 
activity. The observation that MMP-10 expression and activity increased after inhibi-
tion with the selective HDAC3 inhibitor; MI192, in contrast to the general class I 
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HDACi MS275, further supports a role for HDAC3 expression and subsequently 
HDAC3 activity in the regulation of MMP-10 expression and activity, over other class 
I HDACs. This role is further reinforced by silencing of HDAC3 in H460 cells which also 
resulted in an increase in MMP-10 expression and activity of MMP-10 with the results 
demonstrating an increase in active MMP-10 following successful silencing of HDAC3, 
reinforcing the involvement of HDAC3 in the regulation of MMP-10. 
Several studies have indicated a close relationship between HDAC7 and HDAC3 in the 
control of biological functions (Fischle et al., 2002; Fishcle et al., 2001). For instance, 
in cancer cells HDAC3 and HDAC7 collaboratively suppress expression of autotaxin, a 
secreted glycoprotein responsible for production of lysophosphatidic acid (LPA) in-
volved in cancer progression, including NSCLC (Li et al., 2014). Whereas down-regu-
lation of HDAC3 facilitates histone acetylation in the ATx promoter, concomitant 
down-regulation of HDAC7 was required to induce ATx expression (Li et al., 2014). 
These data suggest HDAC3-mediated acetylation of ATx is insufficient and the pres-
ence of HDAC7 is needed to ‘modulate’ HDAC3 activity, a scenario in agreement with 
the control of MMP-10 expression and activity in this current study.  
The observation that HDAC7 and HDAC3 have opposing effects on osteoclast differ-
entiation is also supportive of this study regarding regulation of MMP-10 in NSCLC 
(Pham et al., 2011). In osteoclasts although HDAC3 activity modulates gene expres-
sion, surprisingly, inhibition of class I HDAC with MS275 resulted in a decreased ex-
pression of HDAC7. This suggests HDAC7 expression is under control of class I HDACs, 
with potentially controlling expression directly at the gene level.  
Several studies have reported a direct relationship between the class II HDAC; 
HDAC7, and the class I HDAC; HDAC3 (Fischle et al., 2002; Fischle et al., 2001). In this 
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perspective, HDAC7 is postulated to regulate nuclear-cytoplasmic translocation of 
HDAC3 and thus its enzymatic activity because HDAC3 can only exhibit its deacety-
lase activity when located within the nucleus of the cell. 
The effects of HDAC7 are mediated through a mechanism independent of deacety-
lase activity, with the deacetylase domain of HDAC7 dispensable for repression of 
genes required for osteoclast differentiation (Pham et al., 2011). This deacetylase-
independent role for HDAC7 supports the observations in this study in which HDAC7-
inhibition did not affect MMP-10 expression or activity, whereas down-regulation of 
HDAC7 expression resulted in upregulation of MMP-10 function. Consequently, the 
function of class IIa HDACs is now believed to regulate ‘transportation’ of class I 
HDACs (and other proteins, including transcription factors) between the cytoplasm 
and their functional workplace in the nucleus (Fischle et al., 2001). This is evidenced 
by the observation by Fischle and colleagues demonstrating that in vivo HDAC7 is 
associated with enzymatic activity when located in the cell nucleus but not when lo-
cated in the cytoplasm (Fischle et al., 2001). The lack of the mechanistically important 
Tyr306 and its replacement with a histidine in the active site of HDAC7 (and other 
class IIa HDACs) creating a largely non-functional deacetylase enzyme activity addi-
tionally supports a function for HDAC7 as an acetyl-lysine reader similar to bromo-
domains (Arrowsmith et al., 2012). In this case, HDAC7 is essential for modulating 
expression of key genes with the deacetylation activity being contributed by class I 
HDACs, especially HDAC3, and both enzymes being associated with specific core-
pressors (Fischle et al., 2001). Such a relationship is strongly supported by this study, 
with HDAC3 enzymatic activity and HDAC7 presence being central to regulation of 
MMP-10 and its ultimate proteolytic activity. 
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As described previously, HDAC7 and HDAC3 constitute members of large transcrip-
tional repressor complexes containing SMRT and N-CoR corepressors (Fischle et al., 
2001), and in the case of MMP-10 regulation the transcription factor myocyte en-
hancer factor 2 (MEF2) (Chang et al., 2006). In this complex, the carboxy-terminus of 
HDAC7 interacts with HDAC3, whereas SMRT (also known as N-CoR2) interacts with 
HDAC3 through its deacetylase activating domain (DAD) and to HDAC7 via interaction 
with the second zinc ion located on the surface of the catalytic site of the enzyme 
(Codina et al., 2005; Bottomley et al., 2004). Thus the catalytically inactive HDAC7 is 
recruited into the SMRT repressor complex whose deacetylase activity is conferred 
by adjacently bound HDAC3 (Fischle et al., 2001; Desravines et al., 2017), with the 
interaction resulting in presentation of enzymatically active HDAC3 and locationally-
regulation through conformational and post-translational modulation of HDAC7.  
As discussed by Falkenberg & Johnstone (Falkenberg & Johnstone, 2014), the physi-
cal or enzymatic effect of one HDAC on activity of another HDAC or HDACs as part of 
a multiprotein complex is often overlooked and subsequently underappreciated. For 
instance, the findings from this study have shown both HDAC7 and HDAC3, as part 
of a larger complex, are required for regulation of MMP-10 expression and activity in 
NSCLC. This co-dependence has also been demonstrated by the class IIa HDAC4, 
which also interacts with HDAC3 in a NCoR-SMRT complex, and is essential for re-
pression of genes involved in other cellular systems (Fischle et al., 2001) and regula-
tion of calmodulin dependent protein kinase II (CaMKII) through association with the 
class IIa enzyme, HDAC5 (Backs et al., 2008).  
This HDAC7-NCoR-SMRT-HDAC3 complex is central to regulation of MMP-10, provid-
ing an explanation as to why inhibition of HDAC7 enzymatic activity did not affect 
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MMP-10 expression but inhibition of HDAC3 activity and presence of HDAC3/HDAC7 
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VI Discussion 
Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for 
more than 1 million fatalities per year; more than breast, colon and prostate cancers 
combined. The majority of lung cancer cases are diagnosed after the lung cancer has 
spread to other areas of the body (~60 percent), making it more difficult to treat. 
Despite therapeutic advances, the overall 5-year survival still remains at only 15% 
(Zappa & Mousa, 2016), therefore novel treatment strategies are needed to improve 
patient outcomes. One promising treatment strategy involves the further subdivision 
of NSCLC into clinically relevant molecular subtypes based on specific driver muta-
tions, rather than the histological consideration as previously done. These specific 
driver mutations occur in genes that encode signalling proteins crucial for cellular 
proliferation and survival (Pao & Girard, 2011). One particular gene of interest is the 
secreted endoproteinase; MMP-10, because it has been found to be overexpressed 
in many cancers, including NSCLC (Gill et al., 2004). Although the role of this protease 
in cancer has not yet been elucidated, several studies have demonstrated links be-
tween MMP-10 and tumour pathophysiology (Chang et al., 2006). In NSCLC, MMP-
10 expression and activity is elevated in both primary and metastatic disease (Justil-
ien et al., 2012), but does not associate with tumour sub-type or pathogenesis (Gill 
et al., 2004). Elevated MMP-10 is central to regulation of vascular development; it 
induces remodelling of vascular extracellular matrix, capillary tube regression and 
vascular collapse (Chang et al., 2006). The ability of MMP-10 positive NSCLC cells to 
form tumours in MMP-10-null mice implicates expression of MMP-10 in the tumour 
mass rather than the tumour microenvironment as being key to regulation of tumour 
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growth (Justilien et al., 2012). The importance of tumour-expressed MMP-10 to tu-
mour growth is reiterated by studies by Gill et al, in which supraphysiological induced 
expression of MMP-10 in H460 NSCLC xenografts resulted in retardation of tumour 
growth in vivo. However, induced expression did not alter in vitro growth or survival 
consequently, despite being central to establishment and maintenance of the stem-
cell phenotype. Therefore, understanding the molecular mechanisms underlying reg-
ulation of MMP-10 has important implications for lung cancer pathogenesis and 
identification of therapeutic opportunities. 
MMP-10 regulation has been linked to the histone deacetylase; HDAC7, particularly 
in regulation of vascular integrity (Chang et al., 2006). HDAC7 is thought to repress 
MMP-10, and has found to be under expressed in several types of cancers, including 
NSCLC. Class IIa HDACs possess a conserved C-terminal catalytic HDAC domain and 
interact with myocyte enhancer factor 2 (MEF2) transcription factors through an N-
terminal 17-amino acid motif. This interaction leads to the recruitment of class IIa 
HDACs to select promoters, where MEF2 is bound, resulting in the repression of its 
transcriptional activity. The repressive activity of class IIa HDAC; HDAC7 is tightly reg-
ulated by nucleoplasmic shuttling and by their phosphorylation dependant associa-
tion with the intracellular 14-3-3 proteins. Phosphorylation of conserved residues in 
the N-terminal regions of HDAC7 in response to cellular signals leads to interaction 
with 14-3-3 proteins, dissociation of the class IIa HDAC-MEF2 complexes and a con-
formational change culminating in export from the nucleus (Parra et al., 2004). Sub-
sequently, in addition to MMP-10 facilitating maintenance of the cancer stem cell, a 
role for MMP-10 is postulated in the control of tumour angiogenesis and ultimately 
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metastatic potential (Chang et al., 2006). Timely regulation of MMP-10 is important 
to endothelial motility and vascular development with unregulated activity being 
detrimental to successful angiogenesis, providing an explanation to retardation of 
NSCLC tumour growth in vivo. Unexpected and specific role for HDAC7 in the mainte-
nance of vascular integrity have important implications for understanding the mech-
anisms of angiogenesis and vascular remodeling during cancer development (Chang 
et al., 2006). 
In this study, the silencing of HDAC7 in H460 cells using siRNA resulted in a time-
dependant increase in MMP-10 gene expression. The increase in MMP-10 gene ex-
pression in response to inhibition of HDAC7 gene expression, indicating an inverse 
relationship between these factors, was also accompanied by an increase in proteo-
lytic activity of MMP-10. This elevation of MMP-10 activity occurred post-transcrip-
tionally, supporting regulation at gene level. This result suggested that the proteo-
lytic activity of MMP-10 is significantly increased along with its expression upon 
HDAC7 repression, reinforcing the involvement of HDAC7 in the regulation of MMP-
10 (Herbst et al., 2008). To determine whether the existence of HDAC7 or its enzy-
matic activity is responsible for the effects upon MMP-10, inhibition of HDAC7 activ-
ity was evaluated. However, the inhibition of HDAC7s enzymatic activity using the 
selective IIa inhibitor did not cause a change in MMP-10 gene expression, compared 
to control. In addition, inhibition of HDAC7 enzymatic activity did not alter levels of 
proteolytically active MMP-10. This suggests that although HDAC7 is central to MMP-
10 expression, the activity of HDAC7 has no influence on the regulation of MMP-10 
in vitro. Therefore, although HDAC7 is required for MMP-10 activity, as shown in this 
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study and those investigating vascular development, it is not as straightforward as 
first postulated and is neither a direct acetylation effect nor a ‘conventional’ HDAC 
pathway. However, over the past decade, it has become increasingly apparent that 
histones are not the only targets of acetylation and deacetylation, an abundance of 
non-histone proteins are now known to also be regulated by the actions of HATs and 
HDACs. Acetylation and deacetylation of non-histone proteins have pleiotropic ef-
fects on protein function, including modulation of protein–protein interactions, pro-
tein stability and subcellular localization (Glozak, 2007). Non-histone targets include 
several transcription factors (eg HIF1α), regulatory proteins (eg MLP), and cellular 
structural proteins, such as α-tubulin (Martin et al., 2007). They have also been found 
to be products of oncogenes or tumour-suppressor genes and are directly involved 
in tumorigenesis, tumour progression and metastasis, with aberrant activity of 
HDACs has been documented in several types of cancers (Singh et al., 2010). 
In the past few years, much has been learned about class IIa HDACs, they contain a 
N-terminal extension of ~600 residues which provides a platform for several protein-
protein interactions and post-translational modifications, which enables them to re-
cruit class I HDACs, which are known to be the main drivers of histone deacetylation, 
via transcription co-repressors, which are targeted to specific promoters or subcellu-
lar localization. Examples of these multi protein complexes are the transcriptional co-
repressors; nuclear receptor co-repressor (N-CoR) and silencing mediator for retinoid 
and thyroid hormone receptor (SMRT) (Singh et al., 2010; Fischle et al., 2001). The 
transcriptional corepressors SMRT and NCoR serve as critical mediators of HDAC7 
activity by binding class IIa HDACs and HDAC3 by two distinct repressor domains, 
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suggesting an importance of another HDAC in this regulation of MMP-10 (Fischle et 
al., 2001). 
Inhibition of all the family of HDACs in H460 cells using the pan inhibitor TSA, inhib-
iting both class I and II HDACs, caused a significant increase in MMP-10 expression 
and activity, suggesting the enzymatic activity of one or more HDACs is centrally in-
volved in the regulation of MMP-10 alongside an involvement for presence of 
HDAC7. The previous study results had confirmed class II HDAC activity was not re-
quired for MMP-10 expression, implying an additional involvement for class I HDACs. 
Inhibition of class I HDACs using the sub-family inhibitor MS275 resulted in an induc-
tion in gene expression of MMP-10 by up to 5-fold. However, no significant compar-
ative increase in MMP-10 proteolytic activity was detectable. This confirmed an in-
volvement for class I HDACs alongside HDAC7 in the control of MMP-10 expression 
in NSCLC. The lack of modulation of MMP-10 proteolytic activity with inhibition of 
class I HDACs is likely to be due to the level of MMP-10 expression in the cells, with 
MS275-induced expression being 5-fold compared to 120-fold with the pan-HDACi 
Trichostatin A, with the latter causing a significant increase in MMP-10 proteolytic 
activity. The observation that MMP-10 expression and activity increased after inhibi-
tion with the selective HDAC3 inhibitor; MI192, in contrast to the general class I 
HDACi MS275, further supports a role for HDAC3 expression and subsequently 
HDAC3 activity in the regulation of MMP-10 expression and activity, over other class 
I HDACs. This role is further reinforced by silencing of HDAC3 in H460 cells which also 
resulted in an increase in MMP-10 expression and activity of MMP-10 with the results 
demonstrating an increase in active MMP-10 following successful silencing of HDAC3, 
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reinforcing the involvement of HDAC3 in the regulation of MMP-10. HDAC3, which is 
a class I HDAC, is a nuclear protein that plays a role in regulating multiple genomic 
activities including transcriptional repression (Hudson et al., 2015). Several studies 
have indicated a close relationship between HDAC7 and HDAC3 in the control of bi-
ological functions (Fischle et al., 2002; Fishcle et al., 2001). For instance, in cancer 
cells HDAC3 and HDAC7 collaboratively suppress expression of autotaxin, a secreted 
glycoprotein responsible for production of lysophosphatidic acid (LPA) involved in 
cancer progression, including NSCLC (Li et al., 2014). Whereas down-regulation of 
HDAC3 facilitates histone acetylation in the ATx promoter, concomitant down-regu-
lation of HDAC7 was required to induce ATx expression (Li et al., 2014). These data 
suggest HDAC3-mediated acetylation of ATx is insufficient and the presence of 
HDAC7 is needed to ‘modulate’ HDAC3 activity, a scenario in agreement with the 
control of MMP-10 expression and activity in this current study.  
The observation that HDAC7 and HDAC3 have opposing effects on osteoclast differ-
entiation is also supportive of this study regarding regulation of MMP-10 in NSCLC 
(Pham et al., 2011). In osteoclasts although HDAC3 activity modulates gene expres-
sion, surprisingly, inhibition of class I HDAC with MS275 resulted in a decreased ex-
pression of HDAC7. This suggests HDAC7 expression is under control of class I HDACs, 
with potentially controlling expression directly at the gene level. Several studies have 
reported a direct relationship between the class II HDAC; HDAC7, and the class I 
HDAC; HDAC3 (Fischle et al., 2002; Fischle et al., 2001). In this perspective, HDAC7 is 
postulated to regulate nuclear-cytoplasmic translocation of HDAC3 and thus its en-
zymatic activity because HDAC3 can only exhibit its deacetylase activity when located 
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within the nucleus of the cell. The effects of HDAC7 are mediated through a mecha-
nism independent of deacetylase activity, with the deacetylase domain of HDAC7 
dispensable for repression of genes required for osteoclast differentiation (Pham et 
al., 2011). This deacetylase independent role for HDAC7 supports the observations 
in this study in which HDAC7- inhibition did not affect MMP-10 expression or activity, 
whereas down-regulation of HDAC7 expression resulted in upregulation of MMP-10 
function. Consequently, the function of class IIa HDACs is now believed to regulate 
‘transportation’ of class I HDACs (and other proteins, including transcription factors) 
between the cytoplasm and their functional workplace in the nucleus (Fischle et al., 
2001). This is evidenced by the observation by Fischle and colleagues demonstrating 
that in vivo HDAC7 is associated with enzymatic activity when located in the cell nu-
cleus but not when located in the cytoplasm (Fischle et al., 2001). The lack of the 
mechanistically important Tyr306 and its replacement with a histidine in the active 
site of HDAC7 (and other class IIa HDACs) creating a largely non-functional deacety-
lase enzyme activity additionally supports a function for HDAC7 as an acetyl-lysine 
reader similar to bromo-domains (Arrowsmith et al., 2012). In this case, HDAC7 is 
essential for modulating expression of key genes with the deacetylation activity be-
ing contributed by class I HDACs, especially HDAC3, and both enzymes being associ-
ated with specific corepressors (Fischle et al., 2001). Such a relationship is strongly 
supported by this study, with HDAC3 enzymatic activity and HDAC7 presence being 
central to regulation of MMP-10 and its ultimate proteolytic activity. As described 
previously, HDAC7 and HDAC3 constitute members of large transcriptional repressor 
complexes containing SMRT and N-CoR corepressors (Fischle et al., 2001), and in the 
case of MMP-10 regulation the transcription factor myocyte enhancer factor 2 
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(MEF2) (Chang et al., 2006). In this complex, the carboxy-terminus of HDAC7 inter-
acts with HDAC3, whereas SMRT (also known as N-CoR2) interacts with HDAC3 
through its deacetylase activating domain (DAD) and to HDAC7 via interaction with 
the second zinc ion located on the surface of the catalytic site of the enzyme (Codina 
et al., 2005; Bottomley et al., 2004). Thus, the catalytically inactive HDAC7 is re-
cruited into the SMRT repressor complex whose deacetylase activity is conferred by 
adjacently bound HDAC3 (Fischle et al., 2001; Desravines et al., 2017), with the inter-
action resulting in presentation of enzymatically active HDAC3 and locationally- reg-
ulation through conformational and post-translational modulation of HDAC7.  
As discussed by Falkenberg & Johnstone (Falkenberg & Johnstone, 2014), the physi-
cal or enzymatic effect of one HDAC on activity of another HDAC or HDACs as part of 
a multiprotein complex is often overlooked and subsequently underappreciated. For 
instance, the findings from this study have shown both HDAC7 and HDAC3, as part 
of a larger complex, are required for regulation of MMP-10 expression and activity in 
NSCLC. This co-dependence has also been demonstrated by the class IIa HDAC4, 
which also interacts with HDAC3 in a NCoR-SMRT complex, and is essential for re-
pression of genes involved in other cellular systems (Fischle et al., 2001) and regula-
tion of calmodulin dependent protein kinase II (CaMKII) through association with the 
class IIa enzyme, HDAC5 (Backs et al., 2008). HDAC7, which is thought to have lost its 
deacetylase activity during evolution, could potentially shuttle components of the 
HDAC3-SMRT-NCoR complex, (because it has been found to express both NLS and 
NES) in and out of the nucleus and therefore function as a corepressor, and HDAC3 
alone or in conjunction with other factors would be the sole enzymatic activity of the 
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HDA7-HDAC3 complex, functioning within the nucleus by deacetylating the histones, 
and repressing gene transcription of MMP-10 in vitro. Because the class I HDACs, un-
like the class IIa HDACs, show a significant enhancement of lysine deacetylase activity 
when bound to the corepressor. However, this is a relationship that needs to be fur-
ther explored, to find out by which means this complex exists, which could help in 
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VII Conclusion 
The secreted endoproteinase; MMP-10, has been shown to be overexpressed in hu-
man non-small cell lung cancer (NSCLC), in both the primary and metastatic disease, 
wherein it is proteolytically active and secreted predominantly by tumour cells (Gill 
et al., 2004). MMP-10 over expression has been linked to tumour pathophysiology 
(Chang et al., 2006), its role has been implicated in retarding angiogenesis through 
repression of tumour vasculature development. Elevated levels have shown to in-
duce remodelling of the vascular extracellular matrix, capillary tube regression and 
vascular collapse in vivo (Chang et al., 2006). MMP-10 is involved with vessel for-
mation and stabilization rather than contributing to the invasive nature of tumours, 
an action supported by published studies (Heo et al., 2010). Preliminary data carried 
out by Gill et al., (chapter 1, figure I.3) showed that overexpression of MMP-10 in a 
human NSCLC tumour model did not affect cellular proliferation in vitro, but caused 
significant retardation of tumour growth in vivo, further supporting this role for 
MMP-10 in NSCLC.  
Previous studies have indicated a role for the histone deacetylase (HDAC) enzymes, 
specifically HDAC7, in the regulation of MMP-10, with elevated levels of HDAC7 re-
pressing MMP-10 expression and promoting successful blood vessel formation 
(Chang et al., 2006). The potential that HDAC7 regulates MMP-10 expression and 
vascular integrity has potentially important implications in the treatment of NSCLC 
(Chang et al., 2006). Inhibition of HDAC7 in tumours and consequent up regulation 
of MMP-10 would have antiangiogenic consequences and eventually lead to regres-
sion of tumours due to disruption of the vascular supply (Chang et al., 2006). The aim 
of this project was to evaluate the relationship between MMP-10 and HDACs and 
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whether perturbation of the HDAC7/MMP-10 pathway maybe a viable opportunity 
for therapeutic exploitation in NSCLC. Using an in vitro model of NSCLC, a central role 
for histone deacetylases (HDACs) in regulation of MMP-10 expression was con-
firmed. Although inhibition of HDAC activity increased MMP-10 expression and ac-
tivity, selective inhibition of the class-II HDAC7 had no effect. However, siRNA-medi-
ated repression of HDAC7 expression caused a significant elevation in MMP-10 ex-
pression and activity, supporting a central role for the presence but not enzymatic 
activity of HDAC7 in the control of MMP-10 levels within NSCLC. Despite the lack of 
a role for HDAC7 enzyme activity in control of MMP-10, the initial observation that 
pan-inhibition of HDAC activity repressed MMP-10 expression implicated a wider in-
volvement for HDACs in regulation of MMP-10. Consequently, this study using both 
siRNA and pharmacological inhibitors confirmed an additional role for the presence 
and enzymatic activity of the class-I subfamily member HDAC3 in the regulation of 
MMP-10 in NSCLC.  
These data indicated an interplay between the class-I HDAC3 and class-II HDAC7 in 
the regulation of MMP-10 expression and activity. HDACs are known to form multi-
protein corepressor complexes with nuclear receptors and transcription factors (eg 
HDAC3, -5 and -6 independently form complexes with the SMRT-NCoR complex) of-
fering an alternative mechanism for gene regulation (Jayne et al., 2006). Several stud-
ies have indicated a close relationship between HDAC7 and HDAC3 in the control of 
biological functions (Fischle et al., 2002; Fishcle et al., 2001). For instance, in cancer 
cells HDAC3 and HDAC7 collaboratively suppress expression of autotaxin, a secreted 
glycoprotein responsible for production of lysophosphatidic acid (LPA) involved in 
cancer progression, including NSCLC (Li et al., 2014). Whereas down-regulation of 
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HDAC3 facilitates histone acetylation in the ATx promoter, concomitant down-regu-
lation of HDAC7 was required to induce ATx expression (Li et al., 2014). These data 
suggest HDAC3-mediated acetylation of ATx is insufficient and the presence of 
HDAC7 is needed to ‘modulate’ HDAC3 activity, a scenario in agreement with the 
control of MMP-10 expression and activity in this current study.  
The observation that HDAC7 and HDAC3 have opposing effects on osteoclast differ-
entiation is also supportive of this study regarding regulation of MMP-10 in NSCLC 
(Pham et al., 2011). In osteoclasts although HDAC3 activity modulates gene expres-
sion, surprisingly, inhibition of class I HDAC with MS275 resulted in a decreased ex-
pression of HDAC7. This suggests HDAC7 expression is under control of class I HDACs, 
with potentially controlling expression directly at the gene level.  
Several studies have reported a direct relationship between the class II HDAC; 
HDAC7, and the class I HDAC; HDAC3 (Fischle et al., 2002; Fischle et al., 2001). In this 
perspective, HDAC7 is postulated to regulate nuclear-cytoplasmic translocation of 
HDAC3 and thus its enzymatic activity because HDAC3 can only exhibit its deacety-
lase activity when located within the nucleus of the cell. 
The effects of HDAC7 are mediated through a mechanism independent of deacety-
lase activity, with the deacetylase domain of HDAC7 dispensable for repression of 
genes required for osteoclast differentiation (Pham et al., 2011). This deacetylase- 
independent role for HDAC7 supports the observations in this study in which HDAC7- 
inhibition did not affect MMP-10 expression or activity, whereas down-regulation of 
HDAC7 expression resulted in upregulation of MMP-10 function. Consequently, the 
function of class IIa HDACs is now believed to regulate ‘transportation’ of class I 
HDACs (and other proteins, including transcription factors) between the cytoplasm 
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and their functional workplace in the nucleus (Fischle et al., 2001). This is evidenced 
by the observation by Fischle and colleagues demonstrating that in vivo HDAC7 is 
associated with enzymatic activity when located in the cell nucleus but not when lo-
cated in the cytoplasm (Fischle et al., 2001). The lack of the mechanistically important 
Tyr306 and its replacement with a histidine in the active site of HDAC7 (and other 
class IIa HDACs) creating a largely non-functional deacetylase enzyme activity addi-
tionally supports a function for HDAC7 as an acetyl-lysine reader similar to bromo-
domains (Arrowsmith et al., 2012). In this case, HDAC7 is essential for modulating 
expression of key genes with the deacetylation activity being contributed by class I 
HDACs, especially HDAC3, and both enzymes being associated with specific core-
pressors (Fischle et al., 2001). Such a relationship is strongly supported by this study, 
with HDAC3 enzymatic activity and HDAC7 presence being central to regulation of 
MMP-10 and its ultimate proteolytic activity.  
This study thereby identifies and offers a novel molecular mechanism for HDAC-me-
diated control of MMP-10 in NSCLC, however further work is required to exploit this 
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VIII Overall summary 
Much effort has been made in this project to investigate the regulation of MMP-10 
expression in NSCLC by histone deacetylases, primarily the class IIa member HDAC7 
and subsequently the class I member HDAC3. The major findings from the study were 
i) the importance of HDAC7 physical presence, but not enzymatic activity, in the reg-
ulation of MMP-10 expression and function, and ii) the requirement for HDAC3 en-
zymatic activity to facilitate the HDAC7-MMP10 signalling axis. It is thereby postu-
lated that HDAC7 and HDAC3 demonstrate a physical relationship to regulate MMP-
10 activity, potentially through regulation of nucleoplasmic shuttling, post-transla-
tional regulation of non-histone proteins, and differential interaction with epigenetic 
and genetic regulatory factors. In this context, further studies are proposed to both 
strengthen and confirm the promising findings presented herein and further eluci-
date the molecular mechanisms underpinning these regulatory effects: 
1) Improved definition of the relationship between the HDAC3:SMRT:N-CoR com-
plex. 
· To further elucidate if nuceloplasmic shuttling of HDAC7 and HDAC3 enzymes occur 
in situ, using co-locational fluorescence microscopy methodologies 
· Create truncated and modified HDAC7 and HDAC3 proteins to identify sites of pro-
tein interaction, responsible for physical interaction, co-binding, or co-factor rela-
tional positioning 
2) Involvement of other HDACs in the regulation of MMP-10 activity 
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· Evaluate whether any of the other class IIa HDACs (-4, -5, -9) play a role in the reg-
ulation (positive and negative) of MMP-10 expression and function. 
3) Selectivity of HDAC7-HDAC3 signalling axis toward MMP-10 
· Investigate whether HDAC7:HDAC3 is a generic regulatory mechanism for MMP ex-
pression and activity, or a specific control process for tight control of MMP-10. Ex-
pansion of inhibitor and siRNA studies, presented in this thesis, will permit such eval-
uations. 
4) Confirmation of perturbation of the HDAC3:HDAC7:MMP-10 axis as a clinically val-
idated approach for putative clinical management of NSCLC. 
· Examine the genetic and protein expression of HDAC3, HDAC7 and MMP-10 in spec-
imens of NSCLC and correlations to clinical and pathological parameters, addressing 
potential subcellular co-localisation of these proteins 
· Evaluate therapeutic consequences of selective HDAC3 and HDAC7 inhibition and 
genetic knockdown using preclinical in vivo tumour models, determining effects on 
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Appendix A - Solutions for western blotting 
MRC Lysis Buffer 
Chemical Concentration  
Tris HCl pH 7.5 50mM 
EGTA 1mM 
EDTA 1mM 
Sodium ortho vandate 1mM 
β-glycerol phosphate 10mM 
Sodium fluoride 50mM 
Sodium pyrophosphate 5mM 
Sucrose 0.27M 
Triton x100 1% (v/v) 
β-mercaptoethanol 0.1% 
Mini protease inhibitor 
tablet (Roche, Germany) 
1 tablet per 50ml of 































4x Sample Buffer 
Chemical Concentration 
Tris HCl pH 6.8 240mM 
SDS 8% (w/v) 
Glycerol  40% (v/v) 
Bromophenol blue 0.04% (v/v) 
10% resolving gel 
Chemical Concentration 
Bis/acrylamide 10% (v/v) 
Tris HCl pH 8.8 380mM 
SDS 0.1% 
Ammonium persulfate 0.1% 
TEMED 0.4µl/ml 
5% stacking gel 
Chemical Concentration 
Bis/acrylamide 5% (v/v) 
Tris HCl pH 8.8 750mM 
SDS 0.1% 
Ammonium persulfate 0.1% 
TEMED 1µl/ml 




















Trizma Base 20mM 
NaCl 150mM 


























Trizma Base 250mM 
Glycine 190mM 
SDS 0.1% (v/v) 
Transfer buffer 
Chemical Concentration 
Trizma Base 20mM 
Glycine 150mM 
Methanol 20% (v/v) 
195 | P a g e  
 
Conference Abstract 
Interplay Between Histone Deacetylases in the Modulation of MMP-10 Expression 
in Lung Cancer 
Gallagher N and Gill JH 
School of Medicine, Pharmacy and Health, Durham University, Stockton-on-Tees, UK 
Cancer development is highly dependent upon the Matrix Metalloproteinase (MMP) 
family of proteolytic enzymes. Matrix metalloproteinase-10 (MMP-10) is overex-
pressed in many human carcinomas including non-small cell lung cancer (NSCLC), 
wherein it is expressed, proteolytically active, and secreted predominantly by tu-
mour cells. During mammalian development, MMP-10 is central to regulation of vas-
cular development; elevated MMP-10 induces remodelling of vascular extracellular 
matrix, capillary tube regression and vascular collapse. Such a role implicates an in-
volvement for MMP-10 in tumour angiogenesis, offering a viable target for therapeu-
tic exploitation in NSCLC. Previous studies have shown a role for the class-IIa Histone 
Deacetylase-7 (HDAC7) in regulation of MMP-10 expression, with elevated levels of 
HDAC7 repressing MMP-10 expression and promoting successful blood vessel for-
mation. In this study, we evaluate whether perturbation of the HDAC7/MMP-10 
pathway maybe a viable opportunity for therapeutic exploitation in NSCLC. Using an 
in vitro model of NSCLC, we confirm a central role for histone deacetylases (HDACs) 
in regulation of MMP-10 expression. Pharmacological inhibition of HDAC7 activity 
had no effect on genetic expression of MMP-10, whereas siRNA-mediated knock-
down of HDAC7 expression caused an elevation of MMP-10 mRNA expression. To-
gether this suggests HDAC7 plays a non-enzymatic role in MMP-10 regulation. Sur-
prisingly, pharmacological inhibition of other HDACs, particularly HDAC3 (a member 
of the class-I HDAC sub-family) repressed MMP-10 expression. These data suggest 
interplay between HDAC7 and HDAC3 in the regulation of MMP-10 expression in 
NSCLC. Previous reports have supported a role for HDAC7 in the nuclear shuttling of 
HDAC3, offering a novel molecular mechanism for HDAC-mediated control of MMP-
10 and a potential therapeutic strategy for investigation in NSCLC. 
Poster Presentation; 
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